

PHYSICIAN-FOCUSED PAYMENT MODEL TECHNICAL
ADVISORY COMMITTEE (PTAC)

+ + + + +

PUBLIC MEETING

+ + + + +

Virtual Meeting via Zoom

+ + + + +

Tuesday, February 24, 2026

PTAC MEMBERS PRESENT

TERRY L. MILLS, JR., MD, MMM, Co-Chair
HENISH BHANSALI, MD, FACP
LINDSAY K. BOTSFORD, MD, MBA
LAURAN HARDIN, MSN, FAAN
LAWRENCE R. KOSINSKI, MD, MBA
JOSHUA M. LIAO, MD, MSc
WALTER LIN, MD, MBA
KRISHNA RAMACHANDRAN, MBA, MS
DAVID C. TYSON, MA

PTAC MEMBERS NOT PRESENT

SOUJANYA R. PULLURU, MD, Co-Chair
JAY S. FELDSTEIN, DO

STAFF PRESENT

MARSHA CLARKE, PhD, MBA, COR III, Designated
Federal Officer (DFO), Office of the
Assistant Secretary for Planning and
Evaluation (ASPE)
STEVEN SHEINGOLD, PhD, ASPE

A-G-E-N-D-A

Opening Remarks.....	3
Welcome and Co-Chair Overview - Improving Multi-Payer Alignment in Value-Based Care Day 2.....	3
PTAC Member Introductions.....	4
Session 4: Addressing Challenges to Advance Multi-Payer Alignment.....	12
- Ben Kornitzer, MD; Vivek Garg, MD, MBA; Emily Transue, MD, MHA, FACP; and Rushika Fernandopulle, MD, MPP	
Public Comment Period.....	90
Committee Discussion.....	91
Closing Remarks.....	111
Adjourn.....	112

P-R-O-C-E-E-D-I-N-G-S

9:02 a.m.

*** Welcome and Co-Chair Overview -
Improving Multi-Payer Alignment in
Value-Based Care Day 2**

CO-CHAIR MILLS: Good morning.

Welcome to Day 2 of the public meeting of the Physician-Focused Payment Model Technical Advisory Committee, known as PTAC. My name is Dr. Lee Mills, and I'm one of the PTAC Co-Chairs, along with Dr. Chinni Pulluru.

Yesterday, we had a number of experts share their perspectives on improving multi-payer alignment and value-based care. Today, we have a great lineup of experts for our last session that will focus on addressing challenges to advance multi-payer alignment. The Committee has made considerable effort to include a variety of perspectives throughout this two-day public meeting. Later this morning, we'll have a public comment period and welcome participants to share a comment related to the meeting's topic.

As a reminder, public comments will be limited to three minutes each. If you have not registered to give an oral public comment

1 but would like to, please email
2 ptacregistration@NORC.org prior to the public
3 comment period at 10:50 Eastern Time. Again,
4 that's ptacregistration@NORC.org. Then the
5 Committee will discuss our comments and
6 recommendations that will inform the report to
7 the Secretary of HHS¹.

8 Because we have some new folks
9 online who weren't able to join yesterday, I'd
10 like the Committee members to please introduce
11 themselves, share your name, your organization,
12 and if you'd like, tell us about your
13 experience with our topics. And I'll cue each
14 of you in turn.

15 * **PTAC Member Introductions**

16 CO-CHAIR MILLS: I'll start. I'm
17 Dr. Lee Mills. I'm a family physician. I have
18 the pleasure to serve as Chief Medical Officer
19 of Aetna Better Health of Oklahoma, one of the
20 state's three managed Medicaid plans. Over my
21 career, I've had the pleasure of practicing and
22 leading five or six different CMMI² models over
23 the years from both a health system provider
24 and a payer perspective. Next, let's go to
25 Henish.

1 Health and Human Services

2 Center for Medicare and Medicaid Innovation

1 DR. BHANSALI: Good morning. I'm
2 Henish Bhansali. I'm an internal medicine
3 doctor, primary care practicing by training. I
4 was most recently Chief Medical Officer for
5 Medical Home Network, an enablement entity that
6 worked with Federally Qualified Health Centers
7 across eight states. Prior to that, I was at
8 Duly or DuPage Medical Group as the Senior VP
9 for Medicare Advantage. Duly oversaw or
10 oversees 1.2 million patients in a
11 multidisciplinary fashion. Prior to that, I
12 was at Oak Street and have spent most of my
13 career on value-based care.

14 CO-CHAIR MILLS: Lindsay?

15 DR. BOTSFORD: Thanks, Lee. Good
16 morning. I'm Lindsay Botsford. I'm a family
17 physician in Houston, Texas, where I care for
18 patients of all ages, including Medicare
19 beneficiaries as a PCP³. I'm also the Regional
20 Medical Director for the Midwest and Texas with
21 Amazon One Medical.

22 I've got the pleasure of caring for
23 patients and leading in various ACOs⁴ and value-
24 based payment models for the last 15 years,
25 including the ACO REACH Model, where I

3 Primary care provider

4 Accountable Care Organizations

1 currently serve as the Chair of the Governing
2 Body of the Iora Health Network, formerly led
3 by one of today's presenters, which most
4 recently got 37 million in savings for the 2023
5 performance year. I'll pass it back to you,
6 Lee.

7 CO-CHAIR MILLS: Wonderful. Lauran?

8 MS. HARDIN: Morning. I'm Lauran
9 Hardin, Chief Integration Officer for HC2
10 Strategies and a nurse by training. Our firm
11 is really focused on building cross-sector
12 approaches and multi-payer models; combining
13 and supporting public health, health care,
14 community-based organizations, and states; and
15 coming together to serve complex populations.

16 My background includes many years in
17 serving and designing care management
18 approaches for complex populations, including
19 in many value-based care models, leading a
20 complex care center model that was recognized
21 by the National Academy of Medicine, as well as
22 the American Academy of Nursing. I was part of
23 the team that initiated the National Center for
24 Complex Health and Social Needs out of the
25 Camden Coalition and partnered with many people
26 across the country designing models for complex

1 populations.

2 CO-CHAIR MILLS: Thank you, Laurant.
3 Let's go to Larry.

4 DR. KOSINSKI: Good morning. I'm
5 Larry Kosinski. I'm a retired
6 gastroenterologist. I had a rich career of 35
7 years helping to build the largest GI⁵ group in
8 Illinois, the Illinois Gastroenterology Group,
9 which submitted one of the very first PTAC
10 proposals called Project Sonar, a value-based
11 care solution for GI conditions. It was
12 recommended for testing by PTAC.

13 Since then, that project has become
14 a company, SonarMD, a VC⁶-funded company that's
15 now in multiple states across the country with
16 the same program.

17 I'm also a fractional CMO⁷ for a very
18 interesting AI⁸-powered microbiome company
19 called Jona. And my most recent initiative is
20 a company called BioVOC built around an
21 olfactory device, an e-nose that can help
22 people decide on a healthy diet. I've been on
23 the Committee for five years. I'm looking
24 forward to today's meeting.

5 Gastrointestinal

6 Venture capital

7 Chief Medical Officer

8 Artificial intelligence

1 CO-CHAIR MILLS: Thank you, Larry.
2 Josh?

3 DR. LIAO: Morning, everyone. Josh
4 Liao, internal medicine physician. I spent
5 many years thinking about the topic that we'll
6 talk about today, physician-focused payment
7 models across different payers and how to drive
8 kind of population health and value-based care
9 both from a clinical practice perspective but
10 also a leadership perspective, holding a number
11 of roles over preceding years.

12 I also led a portfolio of research
13 on these topics, looking at things like
14 episode-based payment models, accountable care,
15 and population-based payment models as well.
16 Currently, I continue that work. I also kind
17 of have oversight of enterprise programs at
18 Ascension using technology and capabilities
19 within models to address populations like those
20 insured through Medicare and others. Excited
21 for today's conversation.

22 CO-CHAIR MILLS: All right. Walter?

23 DR. LIN: Good morning, everyone.
24 I'm Walter Lin, internist based in St. Louis,
25 founder of Generation Clinical Partners. We
26 are a medical practice dedicated to helping

1 senior living organizations transition
2 successfully into the world of value-based
3 care. I'm also the chief clinical strategy
4 officer for LTC ACO, and our practice has
5 direct experience with other value-based
6 programs, including bundled payments, PACE⁹, and
7 home-based medical care.

8 CO-CHAIR MILLS: Thank you, Walter.
9 Krishna?

10 MR. RAMACHANDRAN: Thanks, Lee. I'm
11 Krishna Ramachandran, Chief Information Officer
12 in UnitedHealthcare. Twenty-four years in
13 health care in the payer, provider, and health
14 care technology domains, most of it actually
15 furthering value-based care, including efforts
16 on multi-payer alignment. So a topic close to
17 my heart. Thank you.

18 CO-CHAIR MILLS: Thank you. And
19 David?

20 MR. TYSON: Yeah, good morning.
21 David Tyson. I'm the Senior Director of Public
22 Policy at Novant Health, which is a integrated
23 delivery network that spans the Carolinas, 25
24 hospitals over 900 locations. I've been with
25 Novant about 10 years, and that entire time

1 I've focused on all things public policy, but
2 mostly around navigating value-based payment
3 models to help the system sort of understand
4 and move forward in the early days of MIPS¹⁰ and
5 MACRA¹¹, the Medicare Shared Savings Program,
6 and have sort of expanded outward from there
7 and focus and reach.

8 So we currently have about 650,000
9 patients under value-based arrangements across
10 all payers. So looking forward to the
11 conversation today.

12 CO-CHAIR MILLS: All right. Thank
13 you, David. For today's agenda, we're going to
14 explore a range of topics on improving multi-
15 payer alignment in value-based care. The
16 background materials for this public meeting,
17 including an environmental scan, will be posted
18 online at the ASPE PTAC website meeting page
19 and the public meeting registration site.
20 Discussion materials, public comments from this
21 meeting will inform our report to Secretary of
22 HHS on improving multi-payer alignment in
23 value-based care.

24 I'd like to note, as always, that
25 the Committee is ready to receive proposals on

10 Merit-based Incentive Payment System

11 Medicare Access and CHIP (Children's Health Insurance
Program) Reauthorization Act of 2015

1 possible innovative approaches and solutions
2 related to care delivery, payment, or other
3 policy issues from the public on a rolling
4 basis. We offer two possible submission tracks
5 for presenters, offering flexibility depending
6 on the level of detail about payment
7 methodology. And you can find that information
8 about submitting proposals on the ASPE PTAC
9 website.

10 Lastly, on behalf of PTAC, I'm
11 pleased to share the Committee is now producing
12 a series of Issue Briefs that summarize the
13 latest information and evidence related to
14 value-based care that the Committee has
15 explored in its public meetings over prior
16 years.

17 Currently, six Issue Briefs, along
18 with highlights from PTAC's 2020 through 2025
19 theme-based public meetings, are posted on the
20 ASPE PTAC website. The Committee will be
21 publishing new Issue Briefs on additional
22 topics into the very near future. And now I'm
23 excited for this morning's conversation. I'm
24 going to hand the baton over to Lindsay to
25 welcome and facilitate our first session.
26 Lindsay?

1 * **Session 4: Addressing Challenges to**
2 **Advance Multi-Payer Alignment**

3 DR. BOTSFORD: All right. Thank
4 you, Lee. Good morning. I'm Lindsay Botsford,
5 one of the PTAC members that has the pleasure
6 of facilitating this session. So we have with
7 us four experts to discuss their perspectives
8 on addressing challenges to advance multi-payer
9 alignment. You can find their full biographies
10 and slides posted on the ASPE PTAC website and
11 the public meeting registration site. So at
12 this time, I'll ask our session participants to
13 go ahead and turn on your video if you haven't
14 done so already.

15 After all experts have presented,
16 the Committee will have plenty of time to ask
17 questions and engage in what we hope will be a
18 robust discussion. So presenting first, we're
19 pleased to welcome Dr. Ben Kornitzer, who is a
20 Senior Vice President and Chief Medical Officer
21 at Aetna, a CVS Health Company. Ben, welcome.

22 DR. KORNITZER: Great. Thank you so
23 much for having me and glad that I'm out of the
24 blizzard on the east coast that Rushika is
25 dealing with. But I'll be joining you in a few
26 days. I also just want to acknowledge, you

1 know, what a nice reunion this is, seeing so
2 many friends and colleagues in the past couple
3 of years on this as well.

4 So for background, I'm a primary
5 care physician, my own practice focused on care
6 for homebound older adults. I started
7 participating in ACO models really quite early
8 on. We're one of the early community-based
9 ACOs. I spent a number of years as a Chief
10 Medical Officer for Mount Sinai's network in
11 New York, including putting together its
12 clinically integrated network. And so
13 significant time thinking through those models
14 as well.

15 After that, I spent a number of
16 years at agilon, so a senior-focused value-
17 based care enablement organization with largely
18 independent primary care and multi-specialty
19 practices going at risk with different payers
20 around the country. And now the Chief Medical
21 Officer for Aetna, dealing with all lines of
22 business, including our Medicare commercial and
23 Medicaid populations.

24 If we can go to the next page. So
25 we've already seen my bio, so we can move on.
26 So if we talk about, you know, where we are in

1 terms of health care in 2026. I think that,
2 you know, this is a slide that should certainly
3 resonate with everyone. But health care is not
4 delivering the quality of care that patients
5 expect that our country deserves. The costs of
6 care are skyrocketing. Trend year over year
7 is, you know, largely unmanageable. And
8 patient out-of-pocket costs are really
9 preventing them from getting the high-quality
10 care that they want.

11 And so some data that we want to
12 show here. You know, 40 percent of consumers
13 report that they are, you know, delaying care
14 due to that cost of care. And we actually
15 know, and one of the formal precepts of what
16 really good value-based care looks like is it
17 should be longitudinal care, and it should be
18 continuous. And so when people delay that
19 care, that means that their renal disease is
20 worsening. That means that they're at higher
21 risk of having, you know, critical diagnoses,
22 whether they're oncologic or neurologic
23 diseases that could have been prevented. They
24 will miss those opportunities to really
25 intervene.

26 We also know that from a provider

1 angle, care isn't working at all. So, you
2 know, 88 percent of physicians report that they
3 want more time to spend with complex patients,
4 but they're unable to do so. You know, we have
5 phrases in medicine where people measure things
6 like pajama time, right?

7 So the fact that providers are
8 discussing how they're spending their time
9 after hours doing paperwork, not necessarily
10 actually involved in the quality of care and
11 the outcomes, is a major issue. I think it
12 also shows up in the challenges that we have in
13 terms of the access to really high-quality
14 care. And so part of the solution that we need
15 to think through is how do we create that
16 access for those patients, particularly those
17 in most need?

18 And then finally, from the employer
19 lens. So, you know, we deal with a large
20 number of commercial plan sponsors. And I can
21 tell you that every single one of those
22 conversations, there's two things that they
23 bring up. One is ensuring that they get the
24 highest quality of care for their employees.
25 But two, what can they possibly do to really
26 improve the trend, which is unmanageable and to

1 a large extent, almost unpredictable? And so
2 these are really major drivers of where we are
3 in health care in 2026.

4 If we go to the next page. So
5 what's different between fee-for-service and
6 value-based care as we see it through the lens
7 of Aetna, right? So, you know, right now, fee-
8 for-service largely volume-driven. Large
9 number of the costs are really associated with
10 that waste and overutilization, which isn't
11 showing any member benefit whatsoever. But at
12 the same time, we realize that there isn't the
13 quality and value that we want.

14 So I'll talk a little bit later
15 about how we're making sure that, you know, the
16 relationships that we have really drive those
17 quality and value outcomes, including how we
18 think about our networks and who's
19 participating in those networks. And in fee-
20 for-service models, it's really reactive and
21 episodic. And I think there've been a number
22 of great studies actually showing that,
23 particularly within primary care. It's not
24 just the number of touch points that high-risk
25 members have with their primary care provider,
26 but are those being done proactively?

1 And we actually see that downstream
2 utilization is much more manageable when
3 providers have a mentality that they have a
4 ongoing relationship with a member, and it's
5 their responsibility to think through almost
6 for the entire year, you know, what are the
7 appropriate screening tests? What are the
8 check-ins that they need to have? What are the
9 conversations? What are their goals of care or
10 other that are really important? And doing so
11 not in a reactive way, but in a proactive way.

12 That relationship, I think, is
13 absolutely critical. I think two of the
14 biggest gaps we have right now in health care
15 that really pin the right dynamic between
16 payers on a multi-payer model and value-based
17 care for those members is building both trust
18 and long-term relationships. And so I think
19 anything that we do that's going to address
20 better outcomes for members really needs to
21 emphasize that longitudinal nature of that
22 relationship and create that bidirectional
23 trust.

24 And that's what you finally see come
25 to play in the relationship between providers
26 and health plans. And so, you know, when it's

1 a fee-for-service model, it's transactional,
2 it's service-driven, it really becomes a zero-
3 sum game. And when we think about what good
4 value-based care looks like, it's a
5 partnership, right? Value-based care is a team
6 sport. And so it's thinking through how do we
7 actually set up providers to do well in these
8 models? How can we share the right sorts of
9 data, the right insights to set them up so that
10 they can continue on and sustain their
11 practices and really get the best outcomes for
12 the patients they're taking care of?

13 Then we go to the next page. So,
14 you know, historically, there have been some
15 real challenges to adopting value-based care
16 models. So as a primary care doctor, the
17 models are fragmented. So I would have a
18 backpack and go around New York City. I didn't
19 think, well, this is a Medicaid patient, this
20 is a commercial patient, this is a Medicare
21 patient. I thought of my patients as my
22 patients. And so the more that we can reduce
23 that fragmentation and create a seamless
24 experience for providers, I think is absolutely
25 critical.

26 The operational complexity and

1 burden, particularly for smaller practices.
2 And so how do we create solutions that are
3 accessible, actionable? How can we share data
4 that can be easily used by different types of
5 providers so that they're really successful?
6 Create new ways of having data
7 interoperability. We think that that's
8 absolutely critical, that that data needs to be
9 bidirectional, that everyone should be
10 participating, whether it's through the HIEs¹²,
11 whether it's through aligned ACO networks. I
12 think that's absolutely critical.

13 You need a certain amount of
14 financial stability to be able to really invest
15 in long-term primary care. And so making sure
16 that those incentives are meaningful enough,
17 and that providers have the economic
18 wherewithal to really go and participate more
19 meaningfully in value-based care is absolutely
20 essential.

21 And then finally, you need a large
22 population of providers really rallying
23 together. As I mentioned before, value-based
24 care is a team sport. And so one of the things
25 that we see as valuable, for example, coming

12 Health Information Exchanges

1 from the Aetna lens, is because we participate
2 in essentially all lines of business,
3 commercial, Medicare, Medicaid. We can deal
4 holistically with providers in helping them
5 think through how can they create really
6 successful models of care, rather than just
7 sinking through the silos of those individual
8 programs.

9 And then finally, I'll just share a
10 little bit about some of the work that we're
11 doing at Aetna. If we can go to the next page.
12 So we really want to transform the relationship
13 that we have with providers from a
14 transactional one to one where it's a real
15 clinical collaboration.

16 So the way we do that is we work
17 closely with them to make sure that they have
18 access to timely data, that that data is
19 insightful, that they understand where there
20 are opportunities to better manage patients.
21 Whether it's who are their high-risk members,
22 who are people at risk of having readmissions,
23 who are people who haven't been screened for
24 critical conditions, or where we see that they
25 aren't taking important medications.

26 Again, as I mentioned before, our

1 ability to understand what it takes to succeed
2 in that environment, make sure that our network
3 reflects who really are those high-value
4 providers, and make it as transparent as
5 possible, I think is really important. We have
6 teams of clinicians, care managers, performance
7 management capabilities that we can really wrap
8 around these relationships to make sure that
9 value-based care providers do well.

10 We think that the timeliness of data
11 sharing is absolutely critical. I think it's
12 something that, in particular, Aetna has been
13 investing very significantly in, but we also
14 see this across the space. So for example,
15 within Medicare Advantage, we know that our
16 partners who work with us do very, very well
17 when we are able to get them timely
18 information. And we actually see that they
19 improve the quality of that care quite
20 dramatically.

21 Then I think for everything that we
22 do, building up the knowledge base to say that
23 we understand that value-based care really is
24 moving the needle and what are the particular
25 activities that are most impactful, is an
26 investment that we all need to make together.

1 I think this is an opportunity where all ships
2 can rise in the harbor together.

3 Just from our own data within Aetna
4 that we published recently in JAMA¹³ Health
5 Forum, evidence that patients in a value-based
6 care model had significantly better blood
7 pressure control, hemoglobin A1C control, lower
8 admissions, readmissions. That's consistent
9 with data that we've seen from peer
10 organizations around the country.

11 So that gives us conviction to
12 continue to invest in these solutions and make
13 sure that we're giving the opportunity for
14 providers and for our members to get access to
15 what we think is really exceptional high-value
16 care. Thank you.

17 DR. BOTSFORD: Thank you, Ben. So
18 we're going to save all Committee questions
19 until the end of all presentations. So we'll
20 be back. Next, we're glad to welcome back Dr.
21 Vivek Garg, who's President and Chief Executive
22 Officer at the National Committee for Quality
23 Assurance. Vivek, please go ahead.

24 DR. GARG: Hey, good morning,
25 everyone. Great to see many of you again and

1 to see the fellow panelists here. It's really
2 a privilege to be here in front of the
3 Committee again. As Lindsay said, I'm now
4 President and CEO of the National Committee for
5 Quality Assurance, but I spent a number of
6 years as a practicing PCP and internist
7 building clinical programs at new entrants like
8 One Medical and Oscar Health.

9 And then I've spent most of the last
10 decade prior to the NCQA as a CMO in national
11 value-based care groups, supporting complex
12 care models, clinical teams across the country,
13 and trying to move the needle every day on
14 clinical performance and outcomes with
15 organizations like CareMore and CenterWell.

16 I joined the NCQA at the beginning
17 of this year to focus on exactly issues like
18 the Committee is talking about yesterday and
19 today. How do we align our ecosystem to
20 produce the quality and outcomes that Americans
21 deserve while sustaining our health care
22 professional workforce and addressing the
23 societal cost issue?

24 For this conversation, I was asked
25 to focus on a challenge many of you see
26 firsthand, why multi-payer alignment is so hard

1 to achieve in practice, especially in Medicare
2 Advantage. Ultimately, I believe this is
3 really a systems design issue, and a big part
4 of the equation is the quality and outcomes
5 architecture that we deliver through so many
6 different programs and vantage points.

7 For more than 35 years, the NCQA has
8 worked to define and drive health care quality
9 through accreditation, standards, performance
10 measurement, and expert support. But what this
11 has really been about is to help the ecosystem
12 create clarity. Clarity about what good looks
13 like, how to measure it, and how organizations
14 can improve over time. We're fortunate to sit
15 in a neutral and independent position working
16 across stakeholders to help align expectations
17 and accountability.

18 If you go on to the next slide.
19 These are some statistics about the reach of
20 our programs and frameworks like UDS¹⁴
21 measurement. More than 200 million people are
22 covered by health plans that report UDS quality
23 measurement. And almost about 70 percent of
24 Americans are in a NCQA accredited plan, and
25 almost 60,000 clinicians work across more than

14 Uniform Data System

1 11,000 practices that are recognized by
2 programs such as the patient-centered medical
3 home program. So that means our team sees
4 alignment challenges across plans, care
5 delivery, and programs. Not in isolation, but
6 across a very broad swath of the American
7 population.

8 If we go on to the next slide. Here
9 are four main issues that we see. I think they
10 really mirror what Dr. Kornitzer just spoke
11 through, but the first is really trust and
12 transparency in data. If you're operating
13 under a value-based framework with a quality
14 focus, you sometimes don't really know who your
15 patients are. You know them as a clinician,
16 but you don't know them systematically.

17 It can take months to get a full
18 attribution, to have data flow from different
19 plan and policy stakeholder partner programs.
20 And this really drives a lot of fragmentation
21 and incomplete views about clinical utilization
22 and events that are happening, the conditions
23 that people are suffering from, and ultimately,
24 the cost drivers and intervention opportunities
25 that we're all trying to orient around.

26 Plans aren't always seen as neutral

1 partners, and there's often a lot of variation
2 in the timeliness, accurateness, and
3 completeness of data that's received. The
4 ultimate result of this gap is that clinicians
5 are held accountable for outcomes that they
6 cannot see fully in time to often influence.

7 A second gap is really around
8 misalignment between accountability and
9 control. Clinicians and medical groups under
10 risk need to be accountable for costs that they
11 cannot meaningfully influence, including out-
12 of-network leakage, specialty care, high-cost
13 drug utilization, transportation, and other
14 ancillary benefits.

15 Third, there is a lot of variability
16 across contract terms. Even within Medicare
17 Advantage, which benefits from the uniformity
18 of the Stars framework, performance metrics can
19 vary. Incentives definitely vary. Reporting
20 requirements vary, and rules about what to
21 focus on when and what level of value you can
22 drive from them also vary significantly.

23 And fourth, which I know the
24 Committee has talked much about already, is the
25 multi-payer complexity. Medical groups
26 simultaneously operate in Medicare Advantage

1 under Medicare fee-for-service and ACO
2 programs, as well as Medicaid and commercial
3 programs, each with different signals of
4 success. Ultimately, this means that care
5 delivery organizations face fragmented
6 accountability signals across Medicare
7 programs, making alignment very hard in
8 practice.

9 We go into the next slide. Despite
10 these challenges, we do see opportunities to
11 close the gap. First, like Ben and others have
12 talked about, is to strengthen our investment
13 in primary care to help align delegated risk
14 and payment models with advanced primary care
15 capabilities and the population goals that
16 matter the most. We all know that the U.S.
17 spends single digits of the health care dollar
18 on primary care, and we have so much domestic
19 and global evidence that societies that spend
20 double digits in the mid-teen percent benefit
21 from strongly improved population health
22 outcomes.

23 Second is to harmonize the quality
24 and outcome signals, even just for seniors as a
25 starting point, to align on a core digital
26 measure set spanning Medicare Advantage and ACO

1 programs, covering the areas that matter,
2 prevention, clinical outcomes, patient-reported
3 outcomes, avoidable downstream events that no
4 one wants to have happen to their patients, and
5 supported by standardized data exchange
6 expectations, leveraging national contracts
7 like USCDI¹⁵ and FHIR¹⁶ interoperability
8 standards.

9 The third is to standardize care
10 provider alignment under delegated risk,
11 clarify ownership of risk, unify the data
12 standards, as I mentioned, and make the
13 clinical policy and guidelines more consistent.
14 There's a market gap here where policymakers
15 can step in to really establish the rules of
16 the road. In short, alignment improves when
17 primary care quality and outcomes frameworks
18 and risk ownership are designed to work
19 together.

20 To give one example, if we could go
21 on to the next slide. Obviously, I've spent
22 almost a decade working in the care of seniors.
23 And if you look at our major value-based
24 programs in Medicare, including Medicare
25 Advantage, we're targeting similar populations

15 United States Core Data for Interoperability

16 Fast Healthcare Interoperability Resources

1 but have very different measures of success.

2 MA¹⁷ Stars emphasizes experience,
3 function, plan operations, in addition to
4 clinical outcomes. Under MSSP¹⁸ with APP+¹⁹,
5 there's a more narrow focus on clinical
6 outcomes and utilization, an easier reach in
7 the transition to lead, so far as prioritizing
8 outcomes and utilization with far fewer of
9 those other types of measures.

10 And the result is that, as we all
11 know, medical groups and clinicians caring for
12 the same types of seniors and populations are
13 asked to focus on and invest against different,
14 sometimes conflicting, signals and rewards of
15 success. It's not just the disharmony and what
16 they focus on. It's also about where they can
17 invest and create standardized programs and
18 clinical management focus areas to drive
19 outcomes.

20 It's not that the measures are
21 wrong. It's that taken together, they create
22 more noise instead of a coherent measure
23 architecture, especially when it's compounded
24 by different levels of data quality,
25 timeliness, and different incentive frameworks.

17 Medicare Advantage

18 Medicare Shared Savings Program

19 APM (Alternative Payment Model) Performance Pathway Plus

1 So we really need to think about the shared
2 measurement framework and standardizing so that
3 we can get to this more uniform framework.

4 If we go into the next slide. I
5 know the Committee has spent a lot of time
6 looking at the success of different multi-payer
7 alignment models. I'll just share one that has
8 stood out to the NCQA team under the State
9 Innovation Model, which is New York's many
10 yearslong effort to standardize the focus on
11 primary care.

12 As many of you may know, under this
13 SIM model, New York state replaced several
14 different primary care initiatives with a
15 single unified framework, giving one consistent
16 set of expectations, supports, and
17 transformation standards across plans and
18 practices. It aligned on a standard primary
19 care core measure set. It aligned incentives
20 across Medicaid and commercial plans. It
21 leveraged the NCQA PCMH²⁰ program at some point
22 as well. And it was backed by statewide data
23 exchange through SHIN-NY²¹. And importantly,
24 the implementation allowed flexibility and
25 regional variation because often things are a

20 Patient-centered medical home

21 Statewide Health Information Network for New York

1 little bit different when you get closer to the
2 community.

3 Now, I know the CMS²² analysis around
4 SIM models across the country showed mixed
5 results on costs and outcomes, but models like
6 this were successful in creating alignment and
7 focus and harmonization. And it's possible
8 that different levers are needed to be embedded
9 into these programs and a longer timeline is
10 needed to truly see the impact on population
11 costs in health.

12 The main takeaway for me is that
13 convening payers, getting to even partial
14 alignment, and aligning with care delivery in
15 important domains like primary care, delivers
16 real value and should be a big part of the
17 solution.

18 If we can go on to the next slide.
19 So at the NCQA, we're focused on at least three
20 areas to start where we think we can play a
21 role and support this movement.

22 The first is the transition to
23 digital quality measurement. This is not just
24 about using technology and data because it's
25 available. It's about reducing burden,

1 leveraging the data that is available with
2 standardized mechanisms to enable clinically
3 meaningful quality insights at the point of
4 care and in your real time and aligned across
5 all the different levels of the system because
6 the way that things are being computed would
7 then be the same. This would radically reduce
8 burden and enable much more real time
9 population health management.

10 The second is measure cohesion and
11 alignment. We are starting to talk about how
12 do we evolve HEDIS²³ to focus on populations
13 that matter, bundles of measures that can be
14 aligned on and harmonized across programs and
15 partners, including the domains I mentioned
16 before, cross patient-reported outcomes,
17 midpoints and endpoints around clinical
18 outcomes, avoidable low-value care and
19 avoidable end events that no one wants to
20 happen like strokes and heart attacks and
21 amputations and landing on dialysis.

22 The third is to strengthen the
23 backbone of primary care, behavioral health,
24 and important domains of care. This would help
25 us align across managed care and care delivery

23 Healthcare Effectiveness Data and Information Set

1 with uniform notions of quality and outcome
2 success, and help us establish more data
3 sharing, as well as more of a shared value
4 framework that can address some of the gaps I
5 mentioned earlier.

6 So we see NCQA's role as a neutral
7 and independent convener, leveraging the
8 evidence and best practices to align on what
9 good looks like in quality definitions and
10 measurement, and to work with all the policy
11 stakeholders and constituents to achieve that
12 goal. So thank you for the time today and look
13 forward to the Q&A.

14 DR. BOTSFORD: Thank you so much.
15 So next we're excited to welcome Ms. Emily
16 Transue, who is the Chief Clinical Officer at
17 Comagine Health. Welcome, Emily.

18 DR. TRANSUE: Thank you for having
19 me. I'm going to speak a little bit to a
20 Medicaid perspective today, among other things.
21 Let's go on to the next slide.

22 I'm the Chief Clinical Officer at
23 Comagine Health. We are a national nonprofit
24 health care consulting firm and contractor. We
25 work collaboratively with patients, providers,
26 payers, and other stakeholders, including a

1 number of folks who you've heard from on the
2 panel today and yesterday, to reimagine,
3 redesign, and implement sustainable
4 improvements in health care. We have a number
5 of service lines, including care management,
6 data solutions, quality improvement, and
7 research and evaluation.

8 On to the next slide. My
9 background, prior to coming to Comagine Health,
10 I worked for a number of years as a Medical
11 Director at the Washington State Healthcare
12 Authority, which is the agency in Washington
13 that oversees both Medicaid and public and
14 school employee benefits. And I'll be speaking
15 a lot to the work that we did there in my talk
16 today. We convened the Washington Multi-Payer
17 Collaborative, which created the Primary Care
18 Transformation Initiative, and I'll be talking
19 more about both of those.

20 Prior to that, I have experience as
21 a Medical Director at a managed care plan and
22 also spent many years as a primary care
23 internist at a physician-owned practice. So I
24 come to this question of multi-payer efforts
25 having sat at many seats around the table.

26 Next slide. Starting in 2019, the

1 Washington Healthcare Authority convened a
2 group to develop a new primary care model,
3 working with the state's payers and with the
4 primary care provider community. We had both
5 separate and shared meetings with payers and
6 providers, all of the Medicaid MCOs²⁴ in the
7 state, as well as all of the state-contracted
8 commercial payers were involved.

9 We also included a broad variety of
10 providers looking for diversity in size,
11 location, rural versus urban mix, and payer
12 mix. We invited a neutral convener, which was
13 the folks from the Center for Evidence-Based
14 Policy at Oregon Health and Sciences
15 University. They helped us to maintain
16 antitrust guardrails, among other things. And
17 this work drew on prior multi-payer experiences
18 that our CMO had had in Colorado and elsewhere.
19 I think you've heard a lot already that each of
20 these efforts builds on other efforts, and we
21 were certainly doing that as well.

22 Next slide. This resulted in two
23 memorandums of understanding. The first in
24 2020 established the general principles of the
25 collaborative and agreement on the general

24 Managed Care Organizations

1 structure and key components of the Primary
2 Care Transformation Initiative, which we'll
3 look at in a second. Each of the signatories
4 committed to being part of the initiative and
5 making good faith efforts to implement it.

6 The MOU²⁵ was renewed and updated in
7 2024, with signatories agreeing to ongoing
8 active participation in the work and supporting
9 its strategies. Signatories agreed to adhere
10 to the alternative payment policies for primary
11 care that the group developed, and also to
12 using the Washington Primary Care Practice
13 Recognition Program to inform their provider
14 partnerships and contracting strategies.

15 On to the next slide. This was kind
16 of the background of the Primary Care
17 Transformation Initiative. There were
18 commitments from both payers and providers.
19 Payers committed to aligning payment and
20 incentives, and to increasing financing in
21 primary care measured as a percentage of spend.
22 Providers committed to work to increasing
23 capacity and access, and to applying actionable
24 analytics crossing clinical, financial, and
25 social domains.

25 Memorandum of understanding

1 That was all in support of really
2 experiencing primary care as integrated whole-
3 person care, including behavioral health and
4 preventative services, and having a shared
5 understanding of care coordination and where
6 providers fit in that continuum. The goal was
7 for all of those things to result in aligned
8 measurement of value out of the model,
9 incorporating all of the triple-aim outcome
10 measures. This was kind of the general
11 background we were working from.

12 On to the next slide. I'm going to
13 talk about a number of challenges and how we
14 address these. All of these themes are
15 familiar to you from the last couple of days,
16 as well as your previous work: alignment,
17 convening, trust, assumptions, incentives, risk
18 adjustment, and some specific sticking points.

19 Next page. So alignment is always
20 kind of a bugaboo, I think. Everyone always
21 agrees that alignment is critical, but I joke
22 that many of us interpret that as all of you
23 should align to whatever it is that I am doing.
24 There's a reason for that, which is really that
25 systems are already aligned to the many
26 disparate forces that are influencing them.

1 And any time you try to impose alignment with a
2 given program, you run a risk of pulling folks
3 out of alignment with the other work that
4 they're doing.

5 So for example, if as a state you
6 require all the payers to use a common data
7 platform or portal, a national platform may
8 lose the functionalities in the programs that
9 they've built into their national platform.
10 Similarly, for providers, if you agree as a
11 state to work with a common quality measure
12 set, your Federally Qualified Health Centers
13 are still going to be accountable for the UDS
14 and CHRQ²⁶ measures, so you may not have reduced
15 burden as much as you thought you were going
16 to.

17 I think bottom line, it's really
18 important -- it's really easy to be myopic
19 about alignment within a given model, but it's
20 really critical to be aware of the larger
21 picture and consider the impacts that you're
22 having in a holistic context.

23 To the next slide. In Washington
24 around quality measures, we were helped by the
25 existence of the Washington Common Measure Set,

1 which is a statewide set for contracting that
2 was legislatively mandated in 2014 to try to
3 reduce burden around the many quality measures
4 that are out there.

5 This set is maintained by a multi-
6 stakeholder group called the Performance
7 Measures Coordinating Committee, and we were
8 able to convene a subgroup of that to select
9 primary measures for the Primary Care
10 Transformation Initiative. That included both
11 a primary set and then a secondary set for
12 different populations. Of course, it's always
13 challenging to consider different populations'
14 interests, you use very different measures than
15 pediatricians, for example.

16 The Common Measure Set helped us in
17 Washington. Clearly, at a national level, the
18 increasing use of the CMS Universal Foundation
19 measures has the potential to be a huge
20 facilitator of multi-payer work. I think
21 broadly, having a really commonly accepted and
22 parsimonious measure set is very critical to
23 enabling a multi-payer effort.

24 Next slide. Even when you are
25 working on a state-based program, Medicare is
26 still the elephant in the room. Medicare has

1 such a high percentage of payer mix,
2 particularly in rural areas. Medicare also
3 enables consistency across states for national
4 payers, and many Medicare models have a time
5 horizon that is long enough to justify the
6 investments that all participants make in
7 participating in a multi-payer model.

8 In Washington, we had really hoped
9 that the Making Care Primary Model, which was
10 closely aligned with the model that we were
11 developing, would be able to drive our primary
12 care efforts forward at a speed that wouldn't
13 have otherwise been possible. Obviously, in
14 practice, that didn't exactly work out. But I
15 think that when that alignment with Medicare is
16 possible, it's a tremendous, tremendous force
17 at the Medicaid and state level as well.

18 Next slide. We have heard often
19 that change happens at the speed of trust.
20 Discussion really needs to happen both within
21 and between different groups in a model. We
22 found that there was much more frankness in
23 rooms where we had just providers or just
24 payers. People were willing to say things that
25 they weren't willing to talk about in a larger
26 group, and that really needed to be heard. And

1 at the same time, it was also essential to have
2 meetings together to really build trust and
3 relationships, and also to enable addressing
4 key conflict points.

5 This is a map below of, in the first
6 year of this work, how we convened primary care
7 providers and payers separately and then
8 together. We also really found that having a
9 neutral convener was critical to supporting
10 that trust building, as well as to navigating
11 some of the hazards around antitrust issues and
12 others.

13 Next slide. There are a lot of
14 unstated assumptions, and it's very easy to go
15 happily along through a model and then suddenly
16 realize that people are not talking about the
17 same thing. So a few of those, looking at
18 really is the model intended to increase the
19 overall amount of money in a system, even a
20 subset like primary care, or are you really
21 talking about rearranging or redistributing or
22 changing the timing of how dollars are being
23 spent?

24 Are providers expected to increase
25 the number of patients that they're caring for?
26 The idea of moving away from volume and into

1 value means very different things often to
2 payers and policymakers than it does to
3 providers. Where does downside risk fit into
4 the equation? I think we've seen some real
5 changes in how this is perceived, particularly
6 since the COVID epidemic.

7 Which services and which providers
8 are included in the model? It may seem very
9 simple to say primary care and primary care
10 services, but there's a lot of complexity in
11 defining what is in and out of that, and that
12 has huge impacts on the model. These are the
13 kinds of things that you may not realize are
14 critical assumptions and may forget to address,
15 but really being explicit and clear about this
16 is critical to having a successful model.

17 Next slide. Incentives. Multi-
18 payer efforts are time- and resource-intensive,
19 and it can feel like there's a lot of risk to
20 be engaging for both payers and providers. I
21 think it's important to include both the
22 incentives and requirements. We found it was
23 successful to require payers to come to the
24 table and be part of the conversations.

25 States have a number of different
26 kinds of contract methodologies that they can

1 use to lean on their payers, both on the
2 Medicaid side and on the commercial side. We
3 used a lot of those in different ways in our
4 work. I think it can be really successful to
5 incentivize early adoption and then think about
6 penalties later on. So you're making it worth
7 people's while to participate early,
8 particularly providers, and then later use
9 penalties to pull people in.

10 Really though, a model should be
11 self-sustaining once it's in place. I think it
12 makes sense to really push people to engage,
13 but a successful model ought to be self-
14 sustaining and rewarding to all players
15 involved once it's being used.

16 Next slide. Social risk adjustment.
17 Risk adjustment in general, of course, is
18 critical to equity and to avoid penalizing
19 providers who care for challenging populations.
20 I think a special note, particularly in
21 Medicaid, is that social risk adjustment is
22 also really critical. That's true in Medicaid
23 and also in other programs that address similar
24 populations. So the exchange population,
25 programs for undocumented persons just won't
26 work unless you have social risk adjustment.

1 I don't think it's as important that
2 that be standardized across payers necessarily,
3 but the methodology or methodologies have to be
4 credible to the provider community.

5 Next slide. A number of sticking
6 points will come up. You've heard about many
7 of these. I've talked about some of them.
8 Attribution methodology, data platforms, and
9 reporting, risk adjustment, quality measures,
10 which services and providers are included and
11 excluded. All of these can be standardized.
12 Not all of them necessarily need to be.

13 I think for efficiency's sake, it's
14 essential to build on what you have. For
15 Washington, that included the existence of the
16 Common Measure Set and pre-existing work that
17 had been done around definitions for primary
18 care. But differentiating what you're going to
19 standardize and not, and really, really
20 prioritizing what's essential versus what's
21 just nice to have as you move forward.

22 Next slide. So a couple of lessons
23 from our work to summarize. Alignment, try to
24 think beyond the model that you're working on
25 and look at a much global level -- more global
26 level of alignment. Always move at the speed

1 of trust, otherwise you will think you're
2 accomplishing things, and then they will fall
3 apart when it comes to a crunch point.

4 Be very explicit in confirming your
5 principles, assumptions, and goals. Convene
6 peers and providers and policy folks both
7 together and separately. Think about the use
8 of both positive and negative incentives.
9 Really lean into social risk adjustment,
10 especially in the Medicaid population and
11 similar populations. And when it comes to
12 those sticking points, really try to build on
13 what you already have in a system and then
14 prioritize what's most important. That's it
15 for my slides. I look forward to the
16 discussion.

17 DR. BOTSFORD: Thank you, Emily.
18 Last but not least, we are happy to welcome Dr.
19 Rushika Fernandopulle, who is the Chief
20 Executive Officer at Liza Health. Please go
21 ahead, Rushika.

22 DR. FERNANDOPULLE: It is wonderful
23 to be here with everyone, and thank you for
24 having me. If you go to the next slide,
25 please. So I was going to give a bit of a
26 provider perspective as leading a physician

1 group, but we were not at all a typical
2 physician group. So I'll give you a little bit
3 of context.

4 So I'm a primary care doctor,
5 general internist. About 20-something years
6 ago, I woke up and realized that the current
7 primary care model was fundamentally broken.
8 And I'd spent a lot of my career doing what
9 everyone else did, which is what I call the
10 incremental change model. Maybe we can just
11 tweak it a little bit, whether it was called
12 total quality management or CQI²⁷ or Six Sigma
13 or whatever you want to call it, and sort of
14 decided maybe the thing was rotten to the core.
15 And that we had built a system based on
16 transactions, document code build next, as
17 opposed to based on relationships and actually
18 improving health.

19 So in a fit of craziness in 2004
20 when the doctors didn't do this sort of thing,
21 decided to quit the day job and start a
22 practice, Renaissance Health, and revert to
23 primary care. We want to build a new model
24 from scratch, and I'll talk a little bit about
25 that. We did that for several years. We

27 Continuous Quality Improvement

1 realized that this sort of model -- and this
2 sort of model wasn't just better for patients,
3 but was going to lower total health care costs.

4 We ended up working with some
5 employers, one of the first people to do so.
6 We did a pilot with the Boeing Company in
7 Washington, then called the IOCP, the Intensive
8 Outpatient Care Program, and we were sort of
9 led by a gentleman named Arnie Milstein that
10 many of you may know.

11 We then worked with the casino
12 workers in Atlantic City. Atul Gawande wrote a
13 nice article about us called "The Hot Spotters"
14 that allowed us -- it was a cover story in *The*
15 *New Yorker* in 2011 that allowed us to raise
16 some capital. And I said, I want to try and do
17 this at scale. So we created Iora Health in
18 2011 to try and build this model. We grew that
19 over 10 years, and I'll talk a little bit more
20 about that. We merged with a company called
21 One Medical, and then we sold the combined
22 thing to Amazon, as Lindsay mentioned. And
23 we're now the basis of most of Amazon's care
24 delivery model.

25 So next slide, please. So I thought
26 that if we want to change how we deliver care

1 to people, right? And remember, the basis of
2 Iora was starting from scratch, but what does a
3 care model look like if we're going to do the
4 right thing for patients? And realize you have
5 to change four different things. We have to
6 change the process of how we deliver care.

7 Once you start completely changing
8 the process, you realize you need a different
9 IT platform. You can't do this on Epic or
10 Cerner or Allscripts or Athena, because they
11 were not surprisingly built for the current
12 model of care. That requires sort of a
13 different people and culture. And then
14 probably most importantly, you need to get paid
15 correctly in order to make this work. So let
16 me go through those in turn.

17 So the next slide, please. So the
18 model was very different. A lot of things are
19 now incredibly obvious and lots of people are
20 doing. Remember, we started doing this in
21 2004. People thought we were out of our minds.
22 We thought, again, the job to be done was not
23 see one patient at a time and do the best job
24 you can, build as high as you can, move to the
25 next one. But the job to be done would be the
26 population of people. They are our problem.

1 How do we improve their health, keep them out
2 of trouble, and do whatever it takes?

3 And so yes, we have doctors. Their
4 job, as doctors, is to diagnose and prescribe.
5 The hard part is not that. And what we do is
6 we see people in a visit, we tell them what to
7 do, and we say, good luck, sucker, I'll see
8 you, and we pick a random interval for them to
9 come back, right? That's not very effective.

10 So what we need is to wrap a team
11 around people. So we had people we called
12 health coaches. They're from the community,
13 spoke the language of the people they served.
14 Their job was to really accompany people, the
15 kind of Paul Farmer, who sadly passed away.
16 You know, it was his death anniversary. You
17 know, to really hold their hand what's the
18 right thing to do, kick them in the behind when
19 it's the right thing to do.

20 We also started integrating
21 behavioral health and social work. You know,
22 all this stuff is fairly obvious now. Omni-
23 channel care delivery, proactive and not just
24 reactive. Groups of people, provide transport
25 if you need to, et cetera. So very different
26 care model. Pretty much everyone on the call

1 who's talked about this knows what this model
2 is. It's not that we don't know what this is,
3 by the way. We just have to do it.

4 Next slide. And again, you can't do
5 this -- this care is not a little different
6 than typical care. It's completely different.
7 And you can't do it on Epic or Cerner or
8 Allscripts, right? Because they're fancy
9 billing platforms that were designed to help
10 you charge more and get more 99214 and 99215
11 codes. If you don't care about that, you need
12 a different one. So we created our own, we
13 called it Chirp. It's a care collaboration
14 platform, not really an EHR²⁸. It's more a CRM²⁹
15 than an EMR³⁰, and really helped us do our job.

16 Next. And this is key. Like, you
17 cannot do this in a fee-for-service model. You
18 cannot even kind of do it in a fee-for-service
19 model. I think trying to innovate the care
20 model without innovating the business model is
21 a waste of time. I think that's why a lot of
22 the medical home stuff is a waste of time,
23 right?

24 So we started to the right of this,
25 of the line, where at the very least, we would

28 Electronic health record

29 Customer relationship management

30 Electronic medical record

1 take a primary care case rate. Our first
2 practice in Arlington, we were one of the first
3 direct primary care practices in the country,
4 along with Garrison Bliss in Seattle, and Chuck
5 Kilo in Portland.

6 And a handful of us, where we simply
7 asked our patients -- at the time, payers
8 wouldn't give us a time of day, and we simply
9 asked our patients, look, we're going to try
10 and do something very different. Last I
11 checked, your payer's too stupid to pay us the
12 right way. So last I checked, I took analysis
13 review and not them. So here's the deal. If
14 everyone paid us about \$40 a month, we'll break
15 even. If you're rich, pay us more. If you're
16 poor, pay us less.

17 We then evolved where people would
18 do that. And we went to the payers, and we did
19 our first Boeing pilot. Boeing would give us a
20 fixed case rate. Occasionally, they had some
21 bonuses on it or some shared savings. And
22 eventually, when we moved into the Medicare
23 space, we started doing full risk and taking
24 full 100 percent up and downside risk.

25 The dirty little secret is that
26 primary care is, I think as we mentioned on

1 this by other panelists, are typically five to
2 six percent of total health care spend, and
3 that's completely underinvesting in it. And we
4 ended up, you know, spending 10 to 15 percent
5 on primary care. And what you do, of course,
6 is you then keep people out of the hospital and
7 out of the ER³¹, and the total costs go down.

8 So next slide, please. So we grew
9 this to 49 practices in eight different
10 markets, and you see the map here. We
11 partnered with a number of folks, including
12 Humana, United, CVS, Aetna. You know, we also
13 ended up working with CMS directly to create a
14 model, which was initially called direct
15 contracting that morphed into ACO REACH, which
16 is soon to morph into LEAD³², which allowed us
17 to do this sort of care for -- directly with
18 original Medicare patients, work some Blue
19 Cross plans and also some employers like Boeing
20 and Dartmouth, as I mentioned.

21 If you go to the next slide. I was
22 very proud in 2022, the first complete year of
23 CMMI direct contracting. We were the top in
24 the country of performance, 22.3 percent net
25 savings rate, 22.3 percent net savings rate,

31 Emergency room

32 Long-term Enhanced ACO Design

1 right? Imagine how transformational that would
2 be for the country if we could lower Medicaid
3 costs by 22 percent.

4 By the way, I think there's a
5 problem with CMMI demos where what we do is we
6 do a demo, we get a lot of people in. And what
7 we do is we judge the demo by how the average
8 does. And there are a lot of jokers who come
9 into these things who don't know what they're
10 doing. You know, and instead of judging by the
11 average and a lot of good demos have been
12 thrown out, we should look at the people who
13 actually perform well and say, we should keep
14 you and kick out the people who don't do well
15 and then move forward with the people who
16 actually know how to perform. So in any case,
17 these models work, right? And I think we all
18 know that by now.

19 Next slide. You know, if you ask
20 like, why is it that we perform well? If you
21 look at almost all the people at the top of
22 those -- that chart for CMMI direct contracting
23 is we didn't do what the vast majority of
24 practices did, which is the classic foot on the
25 canoe and foot on the dock and tried to run a
26 practice where we're doing optimizing fee-for-

1 service and optimizing value-based care in the
2 same place. That is a fool's errand. It does
3 not work. It's not a little different, it's
4 completely different. So we just simply made a
5 decision.

6 Again, I'm a doctor. I took notes
7 to serve my patients. I cannot serve them in a
8 fee-for-service model. So we're going to stop
9 doing it. And so our attitude was we're going
10 to be fully in on value-based care. So all of
11 our patients were in a value-based care model,
12 right? I think that is the biggest thing for
13 multi-payer alignment is getting everyone to
14 the value-based care.

15 By the way, I think a mistake the
16 industry has made is saying we're going to move
17 slowly to this new world. I think that's
18 probably the hardest thing because you're then
19 stuck with the foot in the boat. You really
20 have to move there quickly. That's the only
21 viable model.

22 So next slide. So even given we
23 were only doing this, you know, we started our
24 life with single-payer practices. So we
25 started at Dartmouth in Hanover, New Hampshire,
26 with Dartmouth Health Connect. It was a

1 practice that was solely serving Dartmouth
2 College employees.

3 And then over time, what we did is
4 that we thought of it like building a shopping
5 mall. We'd get an anchor tenant like
6 Nordstrom's and then we'd add lots of little
7 other people around them. And so we had
8 Dartmouth in there, and then eventually we
9 added other employers like King Arthur Flour,
10 UnitedHealthcare, gave us a Medicare contract
11 for people.

12 Similarly in Phoenix, we worked with
13 Humana. We were single-payer with Humana for
14 several years. And then we branched out and
15 started seeing people from Devoted, some Boeing
16 commercial patients who were sicker and older,
17 and then did direct contracting within the
18 site. So again, we moved to multi-payer in all
19 of our sites because that was a way that we
20 could actually serve multiple populations.

21 Go to the next slide. So we are not
22 typical, right? The way we got alignment
23 between multiple payers is we simply insisted
24 on it. And there are a few features of that.
25 So one which I think is really important is
26 that our relationship with our payers is one of

1 a long-term trusted partner, not a vendor. We
2 tried very hard not to go through the
3 consultants who would try to bid people every
4 couple of years, treat you like a vendor. No,
5 we are long-term partners.

6 You know, it's funny. Boeing once
7 pointed out, we buy tires for our 787s. What
8 we don't do is say any schmuck who makes tires
9 just come slap them on our plane. Of course
10 they don't. We're going to find a few people
11 who do this well, going to work as partners
12 with them over the long term, and we're going
13 to build better planes that way. And we're
14 going to do -- and by the way, one of our
15 biggest suppliers, it's our health care. So
16 why don't we do that with you too?

17 So long-term agreements are very
18 key. Our first agreements like -- were three-
19 year agreements. At Dartmouth, we moved to a
20 five-year agreement. And then when we did our
21 Humana contract, they were 10-year agreements.
22 Ten years makes a complete difference.

23 And then the seller of the services,
24 Iora, would determine how we get paid. And the
25 buyers either agree or they don't. It's funny,
26 in every other industry in the world, the

1 people who deliver the service decide how they
2 want to get paid. If I open a restaurant, I
3 say, this is how I want to get paid. If you
4 don't like it, don't come here, right? And so
5 the goal is just say no, right? And eventually
6 people come around.

7 Simplifying the arrangements are
8 really, really important, right? We have
9 gotten way too complex in these sort of models.
10 And again, I think in these long-term
11 partnerships, you can actually do that and
12 simplify and then streamline reporting.

13 My favorite payment model is what
14 Jim Kim at Dartmouth and we did. We literally,
15 we decided to build this practice for Dartmouth
16 employees. He said, how do you need to get
17 paid? And I said, look -- and he was self-
18 insured, right, so he could do whatever he
19 wanted. And I said, look, we need really to do
20 this simply. So here's the deal. How much do
21 you pay for primary care right now? And the
22 answer was roughly \$40 per person per month.

23 Of course they paid it per visit
24 with all the ancillaries, but that's what it
25 turned out to be. I said, great, let's double
26 down on primary care. I want \$80 per person

1 per month. My billing was a one-line email
2 once a month. We had 1,800 patients times 80,
3 send me a check. It meant, by the way, that we
4 could ask the question, not is there a billing
5 code for this, but will it help the patient?

6 Now, trust but verify, right? Of
7 course, what we said to Dartmouth is you need
8 to believe that this sort of intensive primary
9 care, value-based care is going to save you
10 money. So every five years, we will get an
11 independent academic to do an evaluation of the
12 praxis. We'll do a case control using RTI³³
13 methodology, propensity matching to take the
14 people in the practice, match a group of people
15 that chose not to join the practice, do a trend
16 over trend analysis.

17 And if, as long as we're saving you
18 money on total health care costs, including the
19 extra primary care you're paying us, we keep
20 going. If not, you should fire us. And
21 actually, you shouldn't fire us because I'll
22 quit because we're wasting our time here. And
23 so that was it. And we've been doing this for
24 15 years now up there, and it continues to
25 work.

1 And then the key is to be willing to
2 adjust both ways. We had places where the rate
3 we picked was too low, and we were transparent
4 about economics. Again, that's a long-term
5 trusted partner. And we adjusted it up. There
6 are places we were getting paid too much. We
7 worked with the Freelancers Union in New York.
8 We're getting paid too much, and we adjusted
9 down the rate, right? And that's the way you
10 work, is you work as partners.

11 So, last slide, please. So a few
12 thoughts on multi-payer alignment for value-
13 based care. So it is absolutely necessary to
14 transform practices. Again, you cannot
15 practice different ways for different payers.
16 We've tried that before with color-coding
17 charts. It's a nightmare. It's morally and
18 practically untenable. You've got to do it one
19 right way, and that leads to better outcomes.

20 The biggest barrier today, by the
21 way, I think is getting the commercial payers
22 on board. You know, who would have thought
23 that Medicare would be leading the way and
24 Medicaid behind them? The commercial payers,
25 despite the rhetoric, have tiny amounts of real
26 value-based care. And then that needs to --

1 and they need to do it for both fully insured
2 and ASO³⁴ lives. I'm happy to talk about that.

3 We need to sync on the model of
4 payment. That's the first thing, that's fee-
5 for-service versus capitation. But then also,
6 as everyone else mentioned, getting risk
7 adjustment quality frameworks reporting aligned
8 is also important. But the biggest one is
9 really aligning around -- we are going to align
10 our practices around treating people in this
11 value-based way. And then again, likely we'll
12 need some government push and allowance for
13 this to not fall afoul of antitrust rules. So
14 I will stop here and looking forward to the
15 questions. Thank you.

16 DR. BOTSFORD: Thank you, Rushika.
17 All right. Thanks to all of the experts for
18 those wonderful presentations. I'm sure
19 there's going to be some questions to follow.
20 So we're going to move into the discussion
21 portion of this session. So at this time, for
22 all the PTAC members, please raise your hand in
23 Zoom if you have questions for our guests.

24 Additionally, we want to encourage
25 our experts to ask follow-up questions of each

1 other. You can signal that you have a question
2 by raising your hand in Zoom. In the interest
3 of ensuring balance across different
4 perspectives, we encourage you to keep your
5 response to a few minutes. All right. With
6 that, I see Krishna, first in line here.

7 MR. RAMACHANDRAN: Thanks. Yeah,
8 excellent job, team. It's great to hear your
9 perspective, just these lived experiences and
10 insights as well. Fantastic. Most of you, I
11 think thematically mentioned the sort of data
12 that is trusted, data that's actionable. And
13 obviously, Rushika, you mentioned this platform
14 you had to create because the core EMR systems
15 didn't work as well.

16 It's a topic close to my heart,
17 given the decade I've spent trying to make it
18 better as well. And much like care delivery, I
19 feel like the data landscape is also
20 fragmented. There's EHRs and portals and data
21 files, and there's a lot of variability there
22 as well in our health care landscape. Curious
23 on any recommendations based on your work on
24 just how do we reduce the fragmentation? What
25 does the path forward look like? I would love
26 just some recommendation insights, particularly

1 as you do this nationwide.

2 DR. FERNANDOPULLE: Well, I have a
3 few thoughts on that, Krishna. And thank you
4 for the question. You're right. And
5 particularly when you're working with, you
6 know, the whole point of doing -- I think this
7 is centered a lot around primary care, and I
8 think everyone who's tried to do real value-
9 based care realizes that we have to rebuild the
10 system, not top-down, but bottom-up, right?
11 Start with the consumer and then move upward.
12 I think that's why these initial ACOs sort of
13 failed, to be quite honest, because we started
14 with the hospital and tried to trickle down.
15 We have to start primary care up.

16 But now if you think -- and primary
17 care has to be a lever. If all you do is
18 change primary care, who cares? Primary care
19 has to be a lever to then rationalize the whole
20 rest of the system. But if we want to do that,
21 we have to get the data from all these other
22 places, right? And that's where the problem
23 comes.

24 And despite what the laws say, we
25 and everyone else who's tried to do this run
26 into all sorts of information blocking that

1 goes on, right? Because both the EHR companies
2 and the health systems and the health plans
3 think that they own the data. I think we have
4 made a strong statement that no, the data
5 actually belongs to the patient. That is the
6 right thing.

7 By the way, many countries who do
8 this better than us, they don't even keep
9 records at the provider or the plan level. The
10 patients -- you know, I was in Thailand in Sing
11 Buri Province, and everyone has a little book
12 that they keep with them in a very guarded
13 place at home. When you go to the doctor, you
14 bring the book, and the doctor looks at the
15 book. He looks at the labs. If he adds a lab,
16 he writes it in, changes the med list, and
17 hands the book back to you. One source of
18 truth, belonging to the patient. That's better
19 than we have, right, with the billions and
20 billions of dollars we're spending.

21 So I think we're now finally getting
22 there. There have been lots of problems with
23 trying to build PHRs³⁵ is, you know, Google and
24 Microsoft and a bunch of people tried this.
25 They weren't very trusted. They probably

35 Personal health records

1 shouldn't be. But I think now, and
2 particularly with AI and with some of the 21st
3 Century Cures Act, ONC³⁶ Final Rule and using
4 the TEFCA³⁷ rails, it's finally starting to
5 happen. That's part of what we're working with
6 on Liza Health. And I do agree with you. We
7 have to fix that.

8 DR. GARG: Yeah. I would just add
9 from the NCQA perspective, the organization
10 spent a lot of time on the digitization of
11 quality measurement, as I mentioned briefly.
12 And I've been taught by the team by the massive
13 levels of data fragmentation, as Rushika said,
14 that exists. And it ultimately comes down to
15 where should the data be tracked, and who
16 should it follow? And my guess is we should
17 all say it's available longitudinally to
18 patients and their families and caregivers.
19 That is not how the data ecosystem is
20 organized. Krishna, I'm sure you know that
21 better than many.

22 You know, there are massive issues
23 around data quality. That's one area that NCQA
24 is going to be spending more time. But I think
25 if you just take a step back and say, will we

36 Office of the National Coordinator for Health Information
Technology

37 Trusted Exchange Framework and Common Agreement

1 get to the kind of universal quality and
2 outcomes signals that really matter based on
3 claims data? No. I think we would posit that
4 you wouldn't. There are many richer things
5 that should guide care in population health
6 management that require interoperable clinical
7 data.

8 And then you get to this data
9 fragmentation issue, and then you start to
10 drill in and say, what is this? Are we really
11 using standardized data models in data exchange
12 mechanisms like FHIR?

13 And many organizations are at much
14 earlier stages of that journey. So we are
15 hearing regularly from plans, analytics
16 partners, health systems about the amount of
17 investment and time and change it would take
18 for them to set up their data and the way that
19 would be required in the future. I think
20 that's something else that needs to be
21 considered, which is not every organization has
22 the scale, the sophistication, or the resources
23 to go in that journey.

24 MR. RAMACHANDRAN: All right. Thank
25 you.

26 DR. TRANSUE: Just one thing I would

1 add to that. Another piece of the question is
2 social data. Because I think to do this work,
3 we also really, really need to be exchanging
4 social data and involving CBOs³⁸ and others in
5 it. And so as we think about building better
6 data systems, let's not forget about that part,
7 because really for this to work, we need that
8 too.

9 MR. RAMACHANDRAN: Great plan.
10 Thank you all.

11 DR. BOTSFORD: All right. Larry?

12 DR. KOSINSKI: Great session this
13 morning. I actually have three questions, one
14 for each of the speakers, but anybody else can
15 join in. But Vivek, my first question for you
16 is, I've been in the leadership of the American
17 Gastroenterological Association for decades,
18 and we are always developing measures and
19 metrics and trying to get them into approval by
20 NCQA so that they can then be incorporated into
21 EHRs and so that we can actually use them
22 clinically. But the time factor takes so long.

23 Are you working on anything to make
24 this more nimble? Because frankly, it takes
25 years to get a measure approved through the

38 Community-based organizations

1 process and then implemented, and we cannot
2 move at that speed. We have to move faster
3 than that.

4 DR. GARG: Yeah, it's a great point.
5 I'm starting to learn about that challenge. I
6 think our own team would say they want to be
7 able to accelerate the process while
8 maintaining the integrity. And maintaining the
9 integrity means the scientific integrity, the
10 feasibility testing. Ultimately, there are
11 going to be ways to enhance that process, but
12 we're also not the only party. As you know
13 well, it's a multi-stakeholder approach.
14 There's a consensus-based process through CMS
15 that Battelle coordinates.

16 So we're all participants in
17 different levels of the process and structure,
18 but we are going to be looking at how can we
19 accelerate our part of the equation while
20 maintaining the scientific and feasibility
21 integrity so that ultimately the measures that
22 get developed and aligned on can be produced in
23 an accurate and insightful way. So no clear
24 answer yet, but yes, that will be in a moment.

25 DR. KOSINSKI: We're going to hold
26 you to that. That's going to be one of your --

1 DR. GARG: And on the flip side
2 would be we have to work across the quality
3 development, measure development ecosystem,
4 including medical professional societies to
5 say, how do we create those universal signals
6 together? And where do we adopt best practice
7 frameworks from each party and use them
8 mutually?

9 DR. KOSINSKI: Well, that's a great
10 statement to help me with my second question
11 because one of my other endeavors at the AGA³⁹
12 has been to convene multiple payers across the
13 country to try to come up with common processes
14 around guideline development, around correct
15 coding initiatives, and around value-based
16 care. But I'm going to address this to Ben and
17 Emily. And putting multiple commercial payers,
18 you guys made -- Emily, I think you made the
19 statement that, you know, we need to convene
20 the payers.

21 Well, when we convene the commercial
22 payers in one room, they'll talk about coding,
23 they'll talk about guidelines with each other
24 in the room. But when it comes to value-based
25 care, they quiet up. They get very proprietary

39 American Gastroenterological Association

1 about their financial arrangements. So tips,
2 how do you get them to open up and work
3 together in the same sandbox instead of trying
4 to one-up each other?

5 DR. TRANSUE: So it's a great --

6 DR. KORNITZER: So --

7 DR. TRANSUE: Go ahead.

8 DR. KORNITZER: Go ahead. Go ahead,
9 I'll follow up.

10 DR. TRANSUE: You know, I think
11 absolutely it's a challenge. I think one piece
12 is really trying to be deliberate. Plans, and
13 I've been on the plan side. So, you know,
14 there's a tendency to say like everything is
15 special sauce, right? It's all special sauce.
16 We don't want to talk about it. But you know,
17 there really are only pieces that are
18 differentiators. And so I think to the extent
19 that you can probe, okay, can we talk about
20 this? Like the structure of the program is not
21 likely to be a special proprietary thing.
22 Really defining out what's proprietary, what
23 people see as something that differentiates
24 them versus not.

25 There will be things that are non-
26 starters, you know, figuring out how people are

1 selecting their patients for case management is
2 not likely to be something that people will
3 talk about. But there are other things that I
4 think you can agree on.

5 So I would say my general answer is
6 bring people together in a room and then be
7 explicit about what you want to talk about and
8 let them be explicit about what they consider
9 to be proprietary and then sort of move forward
10 from the pieces that you can find in common.
11 And in my experience, people tend to open up a
12 little bit.

13 DR. KORNITZER: Yeah. Emily, very
14 much appreciated your sentiments. And Larry, I
15 think it was a great question. You know, I can
16 step back and say the previous role, you know,
17 I had worked for an organization that had a
18 value-based contracts across a number of
19 payers. And so very familiar with navigating
20 that environment.

21 You know, what I would say is this,
22 first of all, we should always have the patient
23 at the center of everything that we do. And to
24 the extent that there is clarity on what are
25 the best health outcomes, what are the right
26 measures, like how should we be thinking about

1 managing patients with heart failure and goal-
2 directed therapy? How should we be screening
3 patients for CKD⁴⁰? How should we be ensuring
4 that, you know, older adults are getting high-
5 value tailored care? None of that is
6 mysterious.

7 And so I think that there's probably
8 actually more overlap than there is
9 differentiation from one payer to another.
10 That being said, I think that there's a couple
11 of things that we can do to probably be more
12 effective collaborators. One, we talked a
13 little bit about the alignment of quality
14 metrics and data collection, you know, both
15 across ACO models and Medicare Advantage. I
16 think that will create just a much more
17 streamlined environment so that the
18 conversations on quality will be similar.

19 I think investing in data
20 interoperability, whether it's through HIEs,
21 whether it's making sure everyone's using FHIR
22 standards, again I think those create the
23 chassis that allows it to be much easier for
24 providers to practice high-quality medicine and
25 have reasonable conversations with providers.

40 Chronic kidney disease

1 I think, you know, a challenge has
2 also been longitudinal care. It's impossible
3 to have a fragmented system where a third of
4 your population churns every single year. And
5 so thinking through how do we create longer
6 longitudinal relationships?

7 Quite honestly, there are a number
8 of practices that are probably suboptimal that
9 benefit from patient churn, right? Whether
10 it's deceptive marketing, and so just making
11 sure that we create longer-term runways so that
12 people can make investments, right? If you
13 think about it, if you're a GI and you're doing
14 colonoscopies, you know, there may be a decade
15 before that member actually benefits from that
16 screening. But we need to create situations
17 where everyone benefits from that activity
18 similarly.

19 So, Larry, I hope that sort of gave
20 you some sense of how we're thinking about this
21 and where we think there are opportunities, you
22 know, potentially collaborate differently
23 across different payers, and do it in a way
24 that really benefits members. Thank you.

25 DR. KOSINSKI: Thank you. Rushika,
26 I did not forget you. I saved a question for

1 you, but you're free to comment on anything
2 else that I ask. But I'm really impressed with
3 what you've done. This is phenomenal that you
4 had the vision when you had it to build what
5 you did and how you approached it. I was
6 hanging on everything you wrote, and I have a
7 ton of comments. And one of the things the
8 PTAC Board knows I do is I grab quotes. And
9 I'm going to use yours. Innovating the care
10 model without innovating the business model is
11 a waste of time. I love that. We've talked
12 about that at PTAC.

13 But my question is this, how did you
14 deal with your specialists? How did you bring
15 value-based reimbursement to your specialists
16 when you're at full risk? What was your
17 strategy?

18 DR. FERNANDOPULLE: No, it's a great
19 question, Larry. And I think, as I said, if
20 all you do is innovate primary care, you're
21 wasting your time, right? It's five percent of
22 health care spent. Who cares? It's got to be
23 the lever, which then allows you to rationalize
24 the rest of it. By the way, this whole, we'll
25 let the consumers do this navigation
26 themselves, give them skin in the game and good

1 luck, sucker, like that's a fool's errand too,
2 right? There are such asymmetries of
3 information, asymmetries of power thinking a
4 consumer can do it.

5 But as a primary care doctor, we can
6 actually do that as their partner. By the way,
7 that makes us really important that we are 100
8 percent aligned with the consumer. I think
9 there are too many models where the primary
10 care doctor is actually not working for the
11 patient. They're working for someone else,
12 i.e., the health system or the health plan, et
13 cetera.

14 That's problematic, right? For a
15 lot of reasons. By the way, we would never
16 allow that in financial services. We would
17 call it a conflict of interest, a violation of
18 fiduciary duty. But somehow we allow it to go
19 on in health care, right? So put that aside.

20 So how did we do this, right? So we
21 started by saying it's our job to help people
22 navigate the whole system. And so we started
23 by building what we call good folks list. So
24 we partnered with our health plan. We got as
25 much performance data as we could. You
26 remember, we were doing this a long time ago,

1 the data wasn't that great, but we did as good
2 as we could. And we identified the people we
3 thought were good guys, right?

4 And you can imagine all the things
5 you could look for in the data to do that. And
6 then we go meet with them. And we say, look,
7 so for instance, gastroenterology, it's like,
8 look, here's the deal. We want to look for one
9 GI group that we can work with. And here's
10 what we're looking for. Are you willing to
11 work with us? Let's re-engineer the interface.

12 So when I'm sending for a
13 colonoscopy, I don't need them to meet with you
14 before the colonoscopy. You don't want to
15 waste your time doing that. Tell me what prep
16 you want. I'll do all of that. And then by
17 the way, if it's a normal exam, you don't need
18 to come back to see. I can tell them that.
19 And I can tell you what the follow-up is,
20 right? So we can re-engineer all of those
21 things.

22 By the way, what we found that's
23 interesting is what's more important than
24 finding good folks list is actually finding the
25 bad folks list, a little like Santa Claus.
26 Because there are a handful of specialists in

1 each thing that are just doing egregious
2 things. And we need to make sure our patients
3 never go to those people. So you start with
4 the bad folks list, you then go to the good
5 folks list, and you engineer it.

6 We then eventually started putting
7 some people on retainers. So what if we put
8 you on a little bit of a retainer so that we
9 can actually round together and talk about
10 patients? And people actually really like
11 that. We do it over dinner. We would do a lot
12 of curbside consulting and the like, right?

13 And eventually in some markets when
14 we got to critical skip mass, like in Phoenix,
15 we had 12 practices. We had 20 percent of all
16 the Humana lives at one point. We did then
17 even start hiring some of our own specialists
18 to work with us. So that's -- you know, we
19 have to explicitly do this, build this bottom.
20 What we're building, by the way, is a bottom-up
21 ACO, not a top-down ACO, right? But that's
22 what we all have to get to. Thank you.

23 DR. KOSINSKI: I love that. Thank
24 you.

25 DR. KORNITZER: Yeah. I just want
26 to quickly add to that, that really there's a

1 significant gap, I think, in the relationship
2 between payers and providers, and creating the
3 right trust is so important. I love the
4 thought that, I think Tom Lee said, the way
5 that you get trust is that you give trust. And
6 so just thinking through how we can change that
7 dynamic. And so I'll give you -- since you're
8 a gastroenterologist, helping us understand
9 what are the things that we should be thinking
10 about?

11 So I don't have access to add no
12 detection rates. When I have something getting
13 a speed and colonoscopy, what I really want to
14 know is how good a job is that GI doing at
15 taking their time and finding adenomas, which
16 is the entire purpose? And so figuring out how
17 we can get that type of data so that we can
18 reward those providers who are taking the time,
19 who are thorough, who are getting the best
20 outcomes. And that's part of a bidirectional.
21 We've got work to do on the payer side, and we
22 need to create those bridges. I think that's
23 really what's going to -- when there is that
24 disconnect, I promise you the patients feel it.

25 DR. GARG: And I just want to
26 quickly add to what Ben said. In the absence

1 of that kind of alignment around what real
2 clinical outcomes and excellence look like, and
3 the data sharing can enable that. People are
4 using claims that are mostly looking at cost
5 and their contracting arrangements. And that
6 does not add up to the kind of population
7 health improvement that everybody's
8 individually mostly oriented around in their
9 own practice or the patients want from all of
10 us.

11 DR. KOSINSKI: Thank you, everybody.
12 I've used up enough of our break time.

13 DR. TRANSUE: But just one more sec.
14 I mean, just to call out, I think that was a
15 great answer. And also it only works when
16 you're an independent primary care group and
17 there are independent specialists to contract
18 with that you can pick and choose, which is not
19 the way of the world in general. So it's a
20 huge challenge.

21 DR. KOSINSKI: Great point. Thank
22 you.

23 DR. BOTSFORD: Great point. Lauran?

24 MS. HARDIN: Excellent
25 presentations. Really excited to hear all your
26 diverse perspectives. So I've spent many years

1 really focused on complex populations,
2 definitely designing models in urban
3 environments. But I'm really curious to hear
4 from each of you. Emily, you mentioned social
5 risk adjustment. I'm interested in how -- what
6 kind of unique adaptations, approaches, or
7 supports have you needed to design in for rural
8 environments?

9 I've been involved in frontier
10 environments, Alaska, the border with Mexico,
11 many, many rural communities need that support
12 to be successful in this. So I'm curious how
13 each of you address that and what
14 considerations you may want to share for us to
15 consider as we look at this topic.

16 DR. TRANSUE: Oh, that's such a
17 great question and hard to tie a quick bow
18 around. I mean, I think there are so many
19 fundamental principles around what's happening
20 in a rural setting that are just radically
21 different from what's happening in an urban
22 setting all the way from, you know, it's nice
23 to talk about, let's find the best
24 gastroenterologist that is going to have the
25 highest rates that you could access.

26 But if the only one in a 500-mile

1 radius is, you know, that lady over there,
2 you're going to see that lady over there. I
3 think a lot of the contracting mechanisms kind
4 of break down because again, you can't pick and
5 choose if there are not hospitals and others to
6 pick and choose between.

7 So and then there's trying to
8 understand what cost looks like in a setting
9 that is so different. So many of our
10 mechanisms to control costs kind of hinge on
11 being able to see people in a certain
12 timeframe, being able to send someone home from
13 the hospital and have them follow up the next
14 day, you know, all sorts of things that just
15 aren't possible across that kind of distance.

16 And then there's the additional
17 challenge that so many rural providers are
18 really kind of catastrophically financially
19 struggling. And so you don't have the ability
20 to put the kind of pressure on a system that
21 you would have often in an urban environment.
22 So I think a lot of that is about realizing
23 that especially as you get into those more
24 frontier kind of environments, you're going to
25 have to loosen the rules, you're going to have
26 to have an up-front system that is kind of more

1 generous in how it approaches and assesses
2 impacts.

3 You're going to be really thinking
4 about impacts that are more along the lines of
5 are we maintaining access? Are we keeping
6 providers in the area that are there and need
7 to be there rather than sort of the winnowing
8 down to the most productive few that a lot of
9 models rely on? And again, adapting financial
10 models to recognize the realities of systems in
11 which not every level of care is available and
12 not every kind of follow-up is available.

13 DR. FERNANDOPULLE: So Lauran, I'll
14 just say a couple words. So maybe inherent in
15 your question is that health care is local, and
16 we have to be careful when we build these
17 things, you know, to get alignment. It's not
18 trying to align across everywhere because
19 health care is different. *The New York Times*
20 wrote a great front-page business story on this
21 many years ago. It's called "the Starbucks of
22 health care." Despite my quote saying, this is
23 not like Starbucks, right? You have a
24 Starbucks in one community, they look exactly
25 like one another.

26 But in health care, we have to build

1 for the community, right? The expectations are
2 different, the disease burden is different, the
3 provider landscape is different, the logistics
4 are different, right? So there are some things
5 which we have to do the same because it's the
6 right thing to do, but many things that have to
7 adapt. And we just have to be careful not to
8 over-specify the alignment.

9 You know, we know what to do in a
10 lot of these things. So telemedicine obviously
11 is the right thing to do, home visit teams,
12 helping people with transport and the like.
13 One of our biggest struggles when we, you know,
14 Hanover, New Hampshire, is sort of rural, is
15 it's much easier to attract physicians to work
16 in New York or San Francisco or Boston or
17 Phoenix than it is in, you know, Alaska or
18 Mississippi, et cetera, right? So I think
19 that's part of what the struggle is.

20 We would try to create these sort of
21 fellowship programs where we would sort of get
22 people to be willing to go places and then, you
23 know, in a couple of years, then you can come
24 and work in Seattle or wherever. But by the
25 way, most other countries do things like that.
26 And I think we have to solve the provider

1 shortage issue in these places.

2 DR. GARG: I would just add one
3 thing that NCQA has done is to create managed
4 care and care delivery programming around
5 looking at disparities. And I think part of
6 the impact of what you're flagging are
7 disparities in health and care that exist for
8 the reasons Emily and Rushika were describing.

9 So we have a program called Health
10 Outcomes Quality Accreditation that really a
11 lot of state Medicaid agencies are asking their
12 managed Medicaid MCOs to adopt, which creates a
13 baseline foundation of data to stratify
14 populations by race, ethnicity, disability,
15 other factors, and ultimately say, what are
16 your improvement plans based on the gaps you
17 identify once you stratify that data,
18 leveraging, obviously, best-in-class standards
19 that have been developed nationally?

20 And another partner to that is a
21 community-focused care program to highlight
22 organizations that are adopting robust social
23 needs screening and interventions. And you can
24 imagine the two working hand-in-hand.

25 And that won't -- those things
26 themselves won't solve the problem, but they

1 will hopefully create a more consistent
2 foundation for the partners who adopt them to
3 say, what are we doing, what are the gaps that
4 emerge, whether it's because we're in a rural
5 area or there's specific community dynamics
6 based on the people who are there, based on
7 their experiences and level of health need, and
8 are we closing some of those gaps?

9 DR. KORNITZER: And the only thing I
10 would also add building on that is just, you're
11 considering making the telehealth provisions
12 permanent, given the fact we want providers who
13 are at risk to be able to meet patients where
14 they are, and that's going to be an
15 increasingly diverse population over time.

16 MS. HARDIN: Thank you all.

17 DR. BOTSFORD: All right. We're
18 approaching our last five minutes for
19 discussion here. I'll add a quick one unless
20 there's -- okay, Lee's stepping in. Go ahead,
21 Lee.

22 CO-CHAIR MILLS: Such a great
23 conversation. I was struck, I think, Rushika,
24 you said that, you know, the slow, steady
25 development along the HCPLAN⁴¹ land continuum is

1 a fool's errand because it just prolongs the
2 time you spend with the foot on the dock and
3 the foot in the canoe. Boy, have I lived that,
4 both on the provider and the payer perspective.
5 And so I love the group's thoughts about -- I
6 mean, HCPLAN laid out this wonderful landscape
7 that seems like it's a developmental landscape.

8 But in certain early stages, like
9 the provider has to go through maybe a pay-for-
10 performance because that's when you learn that
11 your data is or is not hooked up, and your EHR
12 code sets are or are not updated to be received
13 and meet NCQA requirements and HEDIS review,
14 all that stuff, right? I mean, that may be an
15 important and necessary developmental step.

16 But I just love your thoughts on
17 what you see has worked contracting and what
18 elements you pull out of different parts of
19 value-based care, and when is the right
20 critical mass to make a jump to full primary
21 care capitation or some other models? Just how
22 do you see that developing compared to how much
23 of the market is trying to do it now?

24 DR. FERNANDOPULLE: You know, so
25 when we did our first Humana contracts, we
26 created explicitly what we called road to risk

1 models. So what we said was, look, we're just
2 starting out, and we did this every market we'd
3 go into. So we would say, it's going to take
4 us a while to build these systems because we
5 don't have them already, right? And to get
6 the, as you said, get this stuff working. So
7 we had roughly three-year road to risk models.

8 Year one, we are just at a primary
9 care cap, right? So we're not at any up or
10 downside risk and just pay us a primary care
11 cap, and this is our sort of get the systems
12 ready. Year two, we would go to, you know, 25
13 percent upside and no downside. Year three,
14 we'd go to sort of 50 percent up and downside.
15 By year four, now we're running at full risk,
16 right? So I think that was really important
17 for us to, sort of, two things. One is to have
18 that clear road and an expectation of when this
19 will happen so you can build for it.

20 The problem today is that it's
21 uncertain, right? If you knew in three years
22 we have to get here, then you can do. And it
23 takes time. It doesn't happen when you snap
24 your fingers. But to put those sort of
25 explicit pathways in place, I think was very
26 helpful.

1 DR. TRANSUE: I would say the
2 pathway also, I like that description. I think
3 there's a distinction between sort of what a
4 carrier is offering and what a provider is
5 choosing. So I think the provider has to move
6 that way, but a carrier can -- doesn't have to
7 say like everybody's got to start early if they
8 already know how to do it. So I think having
9 the opportunity to offer to meet providers
10 where they are in terms of those capabilities
11 is really important.

12 Another thing that I would say, you
13 know, all of those models that you just
14 described were capitation. So it was the fee-
15 for-service part of it, you kind of had out
16 from the beginning and then added the risk, and
17 I think that's a really good model. There's
18 still some challenges. We had a famous example
19 in Washington that resulted in a big lawsuit
20 between an MCO and a direct primary care
21 provider in terms of, you know, are you
22 capitating?

23 Essentially, the root of that was
24 they were capitating a whole bunch of people,
25 and the provider was only seeing about five
26 percent of them, maybe it was 10 percent. So

1 figuring out exactly even what capitation means
2 is important, but I agree that you can fix
3 capitation earlier than risk and be safer.

4 DR. KORNITZER: Let me just add one
5 thought. And I'm a deep believer in value-
6 based care, but, you know, value-based care in
7 and of itself is not necessarily a moral good.
8 The outcome that we really care about is our
9 patients getting better care, and value-based
10 care is a powerful tool that we can use to
11 align people and to get them that outcome.

12 As I think through it, you know,
13 just going back on that comment I made about
14 the relationship between payers and providers,
15 trust is so important, and I think we need to
16 get out of this mindset that it's a zero-sum
17 game and what we should be doing is arm-
18 wrestling over the percentage of premium, but
19 figure out what are the unique capabilities
20 that we as payers have and that providers have,
21 and how we can partner together to get those
22 better outcomes, which is what I think really
23 matters.

24 And I'll be honest, right? You
25 know, when I was on the provider side, even
26 when we had millions of members at risk, we

1 didn't have the sophistication, the data, to
2 really create the predictive analytics, the
3 high-value networks that we needed. And so I
4 think the ability to go and say, how do we set
5 one another up for success, with the idea being
6 that when we have a JOC⁴² in a year from now, or
7 in two years from now, three years from now,
8 you know, we are all going to be delighted with
9 that outcome.

10 And Rushika, I love the example that
11 you gave about whether it was the freelancers
12 union or another, where, as part of the
13 reconciliation, it showed that the dollars
14 weren't where people predicted, and so you made
15 adjustments. When you create a real
16 relationship with people, you're able to do
17 that and do it longitudinally and effectively.
18 And I think that mindset and that partnership
19 is actually really what the key is to create
20 those successful outcomes.

21 DR. BOTSFORD: Thank you. All
22 right, we're in our final few minutes here. If
23 there's any rapid-fire comments from our
24 presenters or things that haven't been said in
25 your final moments, this is it.

1 DR. FERNANDOPULLE: So I just want
2 to thank the PTAC for taking on this issue.
3 This is a huge issue. And like I said, I would
4 push you to focus on the commercial insurers.
5 You know, I think we've already gotten a lot of
6 alignment around Medicare, and Medicare's
7 leading the way, but until we get the
8 commercial insurers on board, it's going to be
9 very hard for the vast majority of practices to
10 actually transform.

11 DR. BOTSFORD: Thank you. All
12 right. Well, I think at this time, I'll go
13 ahead and thank all of our experts here for
14 joining us to kick off Day 2 with some great
15 conversation and for sharing your insights.
16 You're welcome to stay and listen to as much of
17 the meeting as you can, but at this time, we
18 are going to have a break until 10:50 Eastern
19 Time. Please join us then as we welcome any
20 public stakeholders to share comments, and then
21 our day will conclude with a final Committee
22 discussion.

23 (Whereupon, the above-entitled
24 matter went off the record at 10:40 a.m. and
25 resumed at 10:51 a.m.)

26 * **Public Comment Period**

1 CO-CHAIR MILLS: Thanks so much.
2 Welcome back. And now the Committee will
3 discuss everything we learned yesterday and
4 today based on this public meeting. I do need
5 to check in and make sure for the public
6 comment period. I'm not aware that anyone has
7 signed up for public comment. Let me check in
8 with our host. Any public comments online?
9 Hearing none, we will -- last chance. All
10 right. Hearing none, we will proceed with
11 Committee discussion. This closes the public
12 comment section.

13 * **Committee Discussion**

14 CO-CHAIR MILLS: For Committee
15 members, please refer to the potential topics
16 for deliberation document. And if you have a
17 comment, raise your hand in Zoom. We're going
18 to discuss everything we heard yesterday and
19 today and pull out the themes and the pieces
20 that will most inform our report to the
21 Secretary. So, Committee members, please raise
22 your hands. Henish, please go ahead.

23 DR. BHANSALI: Overall, I thought
24 the conversation was fantastic. I think a
25 couple of the key takeaways that I have -- I
26 apologize. Someone is ringing I need to step

1 away.

2 CO-CHAIR MILLS: No worries. We'll
3 pitch it to Lindsay.

4 DR. BOTSFORD: Thanks, Lee. All
5 right. Well, I'm going to channel a former
6 Committee member, Jen Wiler, here and give my
7 top 10 comments or suggestions from today here.
8 You know, I heard a theme from similar
9 meetings, which is extending telehealth
10 provisions would be beneficial as we think
11 about improving value and meeting patients
12 where they are. I heard the importance of a
13 neutral convener, whether that be a state, a
14 neutral party, or maybe the federal government
15 here.

16 And I think three is the theme of
17 trust and needing trust between payers and
18 providers, especially those that come from
19 longer-term relationships than an annual churn
20 cycle. I did also hear using both positive and
21 negative incentives as needed, which is, I
22 think, a theme of maybe the moving faster and
23 moving not slower there. I think as we do all
24 this, don't forget about social risk
25 adjustment. Especially in Medicaid populations
26 as we move quickly.

1 And then some themes around, you
2 know, the potential to build on what you have
3 as opposed to just inventing and trying new
4 things. And again, that concept of simplifying
5 whatever we do have in current state to get us
6 closer to the goal. I also heard potentially a
7 different take on evaluating the CMMI models
8 and different innovation around not just
9 judging by the average performance, but looking
10 at the top performers to think about models
11 that could work.

12 And then the last one is, I think,
13 one we hear almost at every meeting, but that's
14 the importance of data. And despite what might
15 be on paper, the information blocking and
16 data asymmetries are real and need to be solved
17 to be able to get data there. And that's my
18 top 10.

19 CO-CHAIR MILLS: Great. Thank you,
20 Lindsay. Krishna?

21 MR. RAMACHANDRAN: Thanks. And
22 Henish is back. Do you want to finish your --

23 CO-CHAIR MILLS: Go ahead and start,
24 Krishna, and we'll come back to Henish next.

25 MR. RAMACHANDRAN: Okay. Sounds
26 good, yeah. I thought, yeah, fantastic second

1 day as well. Really, yeah, really appreciate
2 the conversation there. Lindsay, I liked your
3 sort of top 10 approach there as well. I think
4 things that stood out, I mean, for two days for
5 me, certainly the, how do we sort of align on
6 the models, right? Whether it's the, you know,
7 the same, same, but different. I think there's
8 a need for us to truly, between Medicare,
9 commercial, getting more alignment. Having
10 consistency in the model certainly came up,
11 which is primarily the theme of this whole
12 discussion there as well.

13 Financial stability continued to
14 sort of be a theme from yesterday and today as
15 well. Like how do we sort of like front-load
16 some of these incentives, make them meaningful
17 to make the transformation? Certainly data
18 interoperability continues to be sort of
19 thematic, sort of a through line as I would
20 expect as well, just given past discussions
21 there we had.

22 And there's speed of trust that came
23 up today as well. How do we sort of, you know,
24 much of the change can -- is going to be
25 limited by how fast we can move from our trust
26 we're building. And so creating spaces where

1 we can have that happen, whether it's an
2 independent convener that is trusted and can
3 take the time to build a trust, I think is key.
4 Harmonization. You know, from a quality
5 measures domain, I appreciated Dr. Garg's
6 comments as well there. I think that too many
7 quality measures too. So how do we sort of
8 streamline, have a common set, I think was
9 helpful.

10 And then particularly with our role
11 PTAC, like where Medicare can lead the way to
12 sort of bring the other stakeholders together,
13 because it's always the, quote, unquote,
14 elephant in the room, as Dr. Transue mentioned
15 there as well.

16 I also liked the unstated
17 assumptions part of it, having spent time on
18 the provider and the payer side on value-based
19 care. I think there's definitely some unstated
20 assumptions in any of these multi-payer
21 efforts. And so putting it on the table where
22 comfortable, I think will also go a long way.
23 I feel like in building trust, creating
24 transparency, but also making sure that
25 everybody's sort of goals are clear as well.
26 So overall -- fantastic two days and great to

1 be part of the conversations.

2 CO-CHAIR MILLS: Thank you, Krishna.
3 And Henish, let's pitch back to you.

4 DR. BHANSALI: Maybe to add a couple
5 of things to what's already been said. One is
6 maintaining the creativity of Medicare
7 Advantage plans or payers while creating some
8 guardrails or maybe some processes that are
9 expected of all Medicare Advantage payers,
10 specifically having to do with attribution, for
11 example. So we learned that there's quite a
12 bit of variability within MA, and we don't want
13 to stifle innovation and creativity.

14 But having some standardized
15 processes in place, whether it be around --
16 well, specifically around data sharing, but
17 also around understanding for risk-bearing
18 entities to understand who the attributed
19 population is early so that the population can
20 be managed. Can things like that be more
21 standardized or expected of Medicare Advantage
22 payers, as it is for other CMMI-CMS programs
23 like MSSP and REACH?

24 The other piece that I heard was
25 around commercial payers, that there isn't
26 nearly as much of value-based care arrangement

1 penetration in that sector. And how can CMS-
2 CMMI be sort of the leader, but have commercial
3 payers follow suit to have VBC⁴³ optionality in
4 that sector?

5 CO-CHAIR MILLS: Okay. Thank you,
6 Henish. Larry?

7 DR. KOSINSKI: Well, I'll add to
8 what I said yesterday at the end of the
9 meeting. As we've said, a little bit more
10 simplification comes out. I like what Lindsay
11 added with consistency. Like, I think CMS
12 needs to have a steady hand on the rudder and
13 guide this instead of continuing to come up
14 with new programs and enforcing that the
15 providers to shift direction. So consistency,
16 simplification, steady leadership in a
17 direction. Hopefully that doesn't change with
18 administrations. But, you know, that came out
19 clear to me.

20 The other word I want to put in is
21 commitment. We heard that, you know, if we
22 don't have CMS at the table, it's difficult.
23 Are they going to invest in the value-based
24 program? How committed are they? But we're
25 going to fail if we don't have a commitment

43 Value-based care

1 from the top. Third thing is, again, we heard
2 it again today from Rushika, you've got to
3 focus on the business model. You have to
4 recognize the success of the business model of
5 the providers or else whatever you do, it's
6 going to fail. We all got to play in the same
7 sandbox.

8 And I love the little nuances that
9 Rushika gave about how he brought specialists
10 in. I heard a new term, retainer. Oh, my God,
11 that's something I haven't heard in any of
12 these meetings. And then the final bullet I
13 have is conveners. I think we need to better
14 define conveners. Because what we heard today
15 is a little different from what we heard from
16 CMS yesterday where you have to be a provider
17 to be a participant. And does the convener
18 have to be a provider? Can the convener be an
19 entity that is not necessarily providing care?

20 So those were my five bullets from
21 the two days. I thought it was a great
22 meeting. I learned a lot. Whoever, the team,
23 PCDT, you've got a lot of credit for picking
24 KOLs⁴⁴ that really made the gears in my head
25 move.

44 Key opinion leaders

1 CO-CHAIR MILLS: All right. Thank
2 you, Larry. David.

3 MR. TYSON: Yeah. So I think I'd
4 echo a lot of what folks have already said.
5 But I think one of the things that came through
6 for me, and maybe this is a place where the
7 PTAC in particular can be more supportive, is
8 this inherent tension between, let's call it
9 incrementalism and rapid adoption. And I think
10 that happens on both the payer and the provider
11 side of things.

12 And a lot of that comes down to
13 trust, trust in incentives, trust in the data,
14 that most folks on the provider side of the
15 house have been sort of loath to jump in with
16 both feet because we've seen that work to
17 varying degrees. And I think that moving into
18 a place of widespread multi-payer sort of like
19 soup to nuts adoption is going to require a bit
20 of hand-holding and a bit more trust-building
21 for sure on the provider side in particular.

22 Because we've heard maybe not
23 explicitly laid out, but just inherently and
24 certainly what Dr. Chernew said of these
25 changing priorities, the shifting landscape
26 that we've seen from administration to

1 administration, none of that builds a lot of
2 trust. And so how do we as the PTAC instill
3 more confidence amongst people? So to Larry's
4 point, maybe PTAC needs to be more of a
5 convener and bring more people to the table.
6 So that was just some of the pieces that stood
7 out to me.

8 CO-CHAIR MILLS: Excellent. Thank
9 you, David. Luran?

10 MS. HARDIN: Agree with all the
11 comments. I think it was an excellent meeting.
12 I'm just going to put some emphasis and
13 repetition on some of those. So one of the
14 biggest themes is this is longitudinal change.
15 So really having the infrastructure in place
16 for a long enough time that the system can
17 actually shift. The core value of really deep
18 emphasis on trust building and the investment
19 in that is really critical to get to shared
20 outcomes, as well as shared value proposition
21 for real change.

22 The investments in capacity
23 building, practice change, and then really
24 strong emphasis on that neutral convener, the
25 integrator role to deeply work on the system
26 improvements for integration to get the impact.

1 And then considering social risk adjustment or
2 other local context adjustments to get long-
3 term change across the board.

4 CO-CHAIR MILLS: Thank you, Lauran.
5 I'll insert myself here and give the final
6 members a few more minutes to think. But I
7 agree with everything that's been pulled out.

8 I was also struck that we heard a
9 lot about, you know, we've spent so much time
10 talking about simplifying metrics in PTAC, and
11 we've talked about programs, but it was
12 interesting to pull out elements of, you know,
13 MA has Stars, states have their own metrics for
14 Medicaid, and yet even inside Medicaid, FQs⁴⁵
15 have their own mandatory measure set. And it
16 clearly is still that it's not that -- it may
17 not so much be that payers can choose to
18 streamline around the CMS core measure set.
19 It's almost driven more of a line of business
20 consideration.

21 And so there's a role, I think, for
22 policymakers to work on trying to get it right
23 now. It feels like we've got 90 percent
24 dispersion, and only 10 percent or less are in
25 common. Maybe there is a role for CMS and

45 Federally Qualified Health Centers

1 policymakers to look at trying to sync up the
2 measure sets for, to a greater degree than
3 there are now, Stars, FQs, ACL⁴⁶ metrics, et
4 cetera. There aren't that many things that
5 truly matter most, right?

6 We heard an element about that, that
7 several people spoke about, it's just important
8 to use MA for critical mass to get above that
9 50, 60, maybe 70 percent threshold of providers
10 involved that major provider and health systems
11 need to get attention and to move the
12 machinery. And I think that was a new element.

13 And I guess the last thing I'll just
14 pull out this element about not thinking of it
15 as incrementalism or incremental development,
16 moving along an HCP⁴⁷ line. At some point, once
17 basic capacities are built, there's a jump,
18 there's a tipping point, to borrow Gladwell's
19 term. And I don't think we've really fully
20 elucidated how that works.

21 And obviously, it'll be different
22 for different people at different places. But
23 maybe that bears more thought and elucidation
24 about what are the metrics or the elements that
25 tell you you're leading up to the tipping

46 Administration for Community Living

47 Healthcare Professional

1 point, and you're ready to jump and skip
2 incrementalism. And so I think that maybe
3 bears further thought in the future, so.
4 Walter?

5 DR. LIN: Thank you, Lee. So I'd
6 like to first begin by just thanking the PCDT,
7 ASPE, NORC, for convening this important
8 discussion on this important topic. The
9 subject matter experts were really great and
10 have given us a lot to think about. So I was
11 inspired by Lindsay's top 10 list just now. I
12 appear to be running only at 50 percent of her
13 insight capacity. So I'm going to offer a top
14 five list.

15 First, again, returning to a theme
16 that we heard yesterday as well. I think our
17 panel this morning emphasized how primary care
18 must really be the anchor in a multi-payer
19 alignment world. Sustained investment in
20 primary care, both in terms of team-based care,
21 as well as the ability to create longitudinal
22 relationships with patients, is the fundamental
23 lever that drives downstream reductions in
24 utilization and improved outcomes.

25 Second, data seems to be the
26 lifeblood of success in multi-payer alignment.

1 Timely, interoperable clinical and social needs
2 data are required so that providers can act
3 proactively, and often today's data
4 fragmentation prevents that.

5 Third, we heard about harmonizing
6 quality measures and performance incentives.
7 This idea of a parsimonious core measure set
8 and the transition to digital quality
9 measurement is critical to reducing
10 administrative burden and to send consistent
11 signals to providers across payers, Medicare,
12 Medicaid, commercial plans.

13 Fourthly, payment design matters.
14 This idea of a staged road to risk pathway, you
15 know, the path that Rushika's companies have
16 taken from taking on case payment, case rate
17 payments to full risk contracts, credible risk
18 adjustment, including social risk, are what
19 really seems to enable providers to make the
20 investments needed to transform care.

21 And fifth, trust and durable
22 partnerships between payer and providers, not
23 short-term transactional vendor relationships,
24 are essential.

25 One kind of concrete idea that came
26 up during our discussion and one I'd like to

1 lift up to the Committee and CMS relates to
2 specialist quality transparency. So Rushika
3 described curating a good folks and a bad folks
4 list to guide specialist referrals, to improve
5 care coordination, and protect patients from
6 low-value or harmful care. This is something
7 that's kind of near and dear to my heart in our
8 current practice and would love the ability to
9 have access to a CMS developed specialist-level
10 performance data list so that PCPs can use to
11 identify high- and low-value specialists
12 locally.

13 It would seem like CMS could, with
14 the help of others, define metrics that matter
15 for specialist performance drawing from the
16 claims data and other sources. And it's going
17 to be important to identify how case mix and
18 social risk adjustment would be handled for
19 fairness. And there'd be a lot of details that
20 would be needed to develop such a list. But I
21 think that would really help primary care
22 practices to reliably build high-value
23 referrals without compromising access and
24 equity.

25 CO-CHAIR MILLS: Thank you, Walter.
26 And I think Josh brings us on home.

1 DR. LIAO: Well, I'll bring you
2 home, going from 10 to five. All I can operate
3 on is three, but I'm cheating because I won't
4 restate many of the things I agree with from
5 other Committee members. But the first thought
6 that I had from a really rich one to two days
7 is really this idea of discipline flexibility.

8 This underscores some of the things
9 that I mentioned yesterday, but I continue to
10 believe that alignment here doesn't equal
11 uniformity. You know, we need flexibility in
12 product design and benefit structure and
13 network configurations. And I think, you know,
14 that is true. At the same time, I think
15 without discipline, that quickly becomes
16 administrative noise. I think some of our
17 subject matter experts highlighted that.

18 I think every additional permutation
19 of quality metrics, attribution logic, and risk
20 adjustment methodology, reporting cadence, adds
21 potential friction to clinicians and
22 organizations who are already operating across
23 Medicare, Medicaid, multiple commercial lines.
24 And I think that really came out.

25 I think just to make that point
26 finer, I don't know that it's a binary choice

1 between standardization and customization and
2 options. I think it's a continuum. I think
3 the work before us as PTAC and others in the
4 policy and practice community is to calibrate
5 that continuum. And I appreciated kind of the
6 humility and pragmatism that I heard from our
7 guests at the meeting about how to go about
8 doing that.

9 I think where variation is essential
10 to preserve product integrity, to give choice
11 to the public for public good, for statutory
12 requirements, we should acknowledge that
13 openly. I think where variation is more
14 historical drift, you know, or competitive
15 signaling, we should think about ways that
16 might be appropriate to narrow that.

17 I think one of the kind of
18 complementary points to this idea of discipline
19 flexibility is to acknowledge that the things
20 that we're talking about are inherently
21 complex, at least to me, because of the models
22 of attribution, risk adjustment, risk
23 corridors, you know, spending adjustments.

24 These are complexities that I don't
25 think we can just pretend can be harmonized
26 away. I think that they're realities we need

1 to focus on. It doesn't mean it's an excuse to
2 maintain variation heterogeneity, but it's just
3 something to acknowledge. And I think where
4 standardization is possible in those things
5 that I mentioned, we should think about
6 meaningful ways to do that. And so I think
7 that's the first thing, discipline flexibility.

8 The second thought that kind of
9 comes to mind is kind of this alignment
10 requires kind of proverbial skin in the game
11 financially. I think, you know, we are the
12 PTAC because I think inherently we recognize
13 that incentives and the way payment occurs is
14 not the most important, perhaps, or the only
15 thing in health care, but it is a very
16 important signal. Some of our subject matter
17 experts underscore that. So I think one of the
18 takeaways for me was that shared expectations
19 without financial consequences or
20 accountability, I worry, may not drive durable
21 change.

22 And so one of the things that came
23 out from our sessions was this kind of
24 leadership and disproportionate focus from
25 Medicare and CMS. And I think that that
26 asymmetry is worth us noting, right? That

1 other segments, including commercial, often
2 trail in scale, in financial commitment, et
3 cetera.

4 And so I think if we want true
5 alignment in the way we're thinking about, not
6 just a CMS-led demonstration with some partial
7 follow-on, I think thinking about what I heard
8 from some of the subject matter experts is, how
9 do we think about making more comparable
10 financial commitment across payers? So I think
11 that needs to be worked out, but I would
12 highlight that, is that we do need that
13 engagement.

14 And then, finally, at the risk of
15 semantics, I was struck by, you know, how we're
16 thinking about what we described in the PCDT as
17 kind of exact versus directional alignment and
18 what is good enough for alignment. And so I
19 hope that one thing we can think about maybe as
20 a step on the way to alignment is this idea of
21 coherence. And so, you know, alignment
22 implying kind of exact or pretty close to
23 shared incentives, accountability, financial
24 architecture.

25 And this may be a good end state as
26 an ideal, but I think given the system that

1 we're in, the heterogeneous benefit designs,
2 statute of requirements, competitive dynamics,
3 all the things we've highlighted and talked
4 about the last few days, I wonder if kind of
5 the concept of coherence, meaning consistent
6 signals, harmonized core elements, you know,
7 de-conflicting operations may be a more
8 pragmatic and durable step. I think that in
9 some ways, I'm trying to name what I've heard
10 from many people today.

11 I will say, I think the distinction
12 matters. I think if we accept alignment as the
13 only acceptable outcome, there is a risk of
14 kind of paralysis in the face of complexity.
15 And so I think the idea of using coherence as
16 an intermediate step there to synchronize all
17 the things we've talked about, measure sets,
18 reporting cadence, attribution, risk
19 adjustment, I do think that can be helpful and
20 really builds the conditions under which I
21 think deeper alignment can be feasible. So
22 kind of thinking about that.

23 So in summary, I think I've heard a
24 lot of good things about challenges and rate
25 limiters of aspirational ideals for alignment.
26 And I think disciplined flexibility, I think

1 making sure there's comparable financial
2 accountability and skin in the proverbial game.
3 And I think thinking about how we cohere, as
4 well as align, in a multi-payer way, I think
5 are some of the things that I'll take away from
6 our meeting this time. Thanks.

7 CO-CHAIR MILLS: Thank you so much,
8 Josh. Great thoughts. Any other final
9 thoughts? I think everybody's had a chance.
10 Okay. Well, thank you to all the Committee
11 members for sharing your valuable insights and
12 the themes summarized over two days of
13 incredibly rich conversation.

14 * **Closing Remarks**

15 CO-CHAIR MILLS: Before closing, I
16 need to check in with the ASPE staff to see if
17 there's any clarifying questions or comments.
18 Marcia, Steve, any dangling threads we need to
19 pull on?

20 MR. SHEINGOLD: No.

21 CO-CHAIR MILLS: Okay.

22 DR. CLARKE: Nothing for me. Great
23 sessions.

24 CO-CHAIR MILLS: All right. Thank
25 you so much. So I'd like to thank everyone for
26 participating today, our session experts, my

1 PTAC colleagues, those listening in, and
2 especially all the amazing staff that made
3 today possible. We explored many different
4 topics regarding improving multi-payer
5 alignment and value-based care. Special thanks
6 to my colleagues. There's a lot of information
7 packed into these two days, a lot of incredible
8 perspectives shared. I appreciate your active
9 involvement and participation and thoughtful
10 comments.

11 * **Adjourn**

12 The Committee will work to issue a
13 report to the Secretary with our
14 recommendations coming out of this theme and
15 from this public meeting. And with that, one
16 final thank you to the Committee and all of our
17 session experts for joining us and making this
18 memorable and informative PTAC public meeting.
19 I will declare this meeting is adjourned.
20 Thank you very much.

21 (Whereupon, the above-entitled
22 matter went off the record at 11:17 a.m.)

C E R T I F I C A T E

This is to certify that the foregoing transcript

In the matter of: PTAC Advisory Committee

Before: PTAC

Date: 02-24-26

Place: virtual meeting

was duly recorded and accurately transcribed under my direction; further, that said transcript is a true and accurate complete record of the proceedings.



Court Reporter

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1716 14TH ST., N.W., STE. 200

WASHINGTON, D.C. 20009-7831